documents incorporated reference table c parts portions registrant 's annual report shareholders ii fiscal year part iii portions registrant 's proxy statement annual meeting table part table caption item c c business general segments business geographic areas consumer pharmaceutical medical devices diagnostics geographic areas raw materials patents trademarks seasonality competition research environment regulation properties legal proceedings submission matters vote security holders executive officers registrant part ii market registrant 's common equity related shareholder matters selected financial data management 's discussion analysis financial condition results operations quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accounting financialdisclosure part iii directors executive officers registrant executive compensation security ownership certain beneficial owners management certain relationships related transactions controls procedures part iv exhibits financial statement schedules reports form k signatures certifications pursuant rule securities exchange act certifications pursuant usc section report independent accountants exhibit index table form q quarterly reports available copy johnson johnson 's quarterly report form q first three quarters current fiscal year without exhibits provided without charge shareholder submitting written request secretary principal executive offices company calling report available days end quarter relates company 's sec filings also available company 's website wwwjnjcom investor relations section part item business general johnson johnson employing approximately people worldwide engaged manufacture sale broad range products health care field operating companies conducts business virtually countries world johnson johnson 's primary interest historically currently products related human health wellbeing johnson johnson organized state new jersey johnson johnson organized principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities domestic international companies span consumer pharmaceutical medical devices diagnostics segments international subsidiary exceptions managed citizens country located segments business johnson johnson 's worldwide business divided three segments consumer pharmaceutical medical devices diagnostics additional information required item incorporated herein reference narrative tabular graphic descriptions segments operating results captioned management 's discussion analysis results operations financial condition description segments consumer pharmaceutical medical devices diagnostics operating results pages johnson johnson 's annual report shareholders fiscal year consumer consumer segment 's principal products personal care products including nonprescription drugs adult skin hair care products baby care products oral care products first aid products women 's health products nutritional products major brands include aveeno skin care products bandaid brand adhesive bandages benecol food products carefree panty shields clean clear teen skin care products compeed foot care products imodium ad antidiarrheal johnson 's baby line products johnson 's ph skin hair care products monistat remedy vaginal yeast infections adult children 's motrin ib ibuprofen products mylanta gastrointestinal products pepcid ac acid controller johnson johnson merck consumer pharmaceuticals co neutrogena skin hair care products ob tampons penaten natusan baby care products piz buin sundown sun care products reach toothbrushes roc skin care products shower shower personal care products splenda noncaloric sugar substitute stayfree sanitary protection products broad family tylenol acetaminophen products viactivcalcium supplements consumer segment 's products marketed principally general public distributed wholesalers directly independent chain retail outlets throughout world pharmaceutical pharmaceutical segment 's principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology fields products distributed directly wholesalers health care professionals use prescription general public prescription drugs antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarin miconazole nitrate antifungal products prescription drugs antiinfective field include floxin ofloxacin levaquin levofloxacin prescription drugs cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drugs dermatology field include retina micro tretinoin dermatological cream acne prescription drugs gastrointestinal field include aciphex rabeprazole sodium proton pump inhibitor treating erosive gastroesophageal reflux disease gerd duodenal ulcers company derives service revenue product copromoted us eisai imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn 's disease patients remicade also indicated treatment rheumatoid arthritis prescription drugs hematology field include procrit epoetin alfa sold outside us eprex biotechnology derived version human hormone erythropoietin stimulates red blood cell production accounted company 's total revenues prescription drugs immunology field include orthoclone okt muromonabcd reversing rejection kidney heart liver transplants prescription drugs neurology field include reminyl galantamine topamax topiramate stugeron cinnarizine prescription drugs oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drugs pain management field include duragesic fentanyl transdermal system sold abroad durogesic transdermal patch chronic pain ultracet tramadol hydrochlorideacetaminophen shortterm management acute pain prescription drugs psychotropics central nervous system field include risperdal risperidone haldol haloperidol concerta methylphenidate attention deficithyperactivity disorder prescription drugs urology field include ditropan xl oxybutynin treatment overactive bladder prescription drugs contraceptive field include orthoevra norelgestrominethinyl estradiol transdermal system orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sold us ortho tricyclen group oral contraceptives sales three largest distributors amerisourcebergen corp mckesson hboc cardinal distribution accounted respectively total revenues medical devices diagnostics medical devices diagnostics segment includes broad range products used direction physicians nurses therapists hospitals diagnostic laboratories clinics products include ethicon 's wound care surgical sports medicine women 's health products ethicon endosurgery 's minimally invasive surgical products cordis ' circulatory disease management products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' professional diagnostic products depuy 's orthopaedic joint reconstruction spinal products vistakon 's disposable contact lenses distribution health care professional markets done directly surgical supply dealers geographic areas international business johnson johnson conducted subsidiaries located countries outside united states selling products virtually countries throughout world products made sold international business include many described description segments consumer pharmaceutical medical devices diagnostics however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed bysubsidiaries abroad investments activities countries outside united states subject higher risks comparable domestic activities investment commercial climate influenced restrictive economic policies political uncertainties raw materials raw materials essential johnson johnson 's business generally readily available multiple sources patents trademarks johnson johnson made practice obtaining patent protection products processes possible johnson johnson owns licensed number patents relating products manufacturing processes aggregate believed material importance operation business however believed except patents related procritexprex single patent related group patents material relation johnson johnson whole johnson johnson made practice selling products trademarks obtaining protection trademarks available means johnson johnson 's trademarks protected registration united states countries products marketed johnson johnson considers trademarks aggregate material importance operation business seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research grants competition product lines johnson johnson companies compete companies large small located united states abroad competition strong lines without regard number size competing companies involved competition research involving development new products processes improvement existing products processes particularly significant results time time product process obsolescence development new improved products important johnson johnson 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition winning retention customer acceptance johnson johnson 's consumer products involve heavy expenditures advertising promotion selling research research activities important segments johnson johnson 's business major research facilities located united states also australia belgium brazil canada germany switzerland united kingdom costs johnson johnson 's worldwide research activities relating development new products improvement existing products technical support products compliance governmental regulations protection consumer amounted million fiscal years respectively costs charged directly income year incurred research sponsored johnson johnson environment past year johnson johnson subject variety federal state local environmental protection measures johnson johnson believes operations comply material respects applicable environmental laws regulations johnson johnson 's compliance requirements expected material effect upon capital expenditures earnings competitive position regulation johnson johnson 's business subject varying degrees governmental regulation countries operations conducted general trend toward regulation increasing stringency unitedstates drug device diagnostics cosmetic industries long subject regulation various federal state local agencies primarily product safety efficacy advertising labeling exercise broad regulatory powers food drug administration fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends toward product process regulation also evident number major countries outside united states especially european economic community efforts continuing harmonize internal regulatory systems costs human health care continue subject study investigation regulation governmental agencies legislative bodies united states countries united states attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend particular medical devices even absence new government regulation managed care become potent force market place likely increased attention paid drug medical device pricing appropriate drug medical device utilization quality health care regulatory agencies whose purview johnson johnson operates administrative powers may subject johnson johnson actions product recalls seizure products civil criminal sanctions cases johnson johnson may deem advisable initiate product recalls voluntarily item properties johnson johnson worldwide subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments johnson johnson 's business approximately follows table caption square feet segment thousands c consumer pharmaceutical medical devices diagnostics worldwide total table within united states facilities used consumer segment pharmaceutical segment medical devices diagnostics segment johnson johnson 's manufacturing operations outside united states often conducted facilities serve one segment business locations manufacturing facilities major geographic areas world follows table caption number square feet geographic area facilities thousands c c united states europe western hemisphere excluding usa africa asia pacific worldwide total table addition manufacturing facilities discussed johnson johnson maintains numerous office warehouse facilities throughout world research facilities also discussed item business researchjohnson johnson generally seeks manufacturing facilities although principally locations abroad leased office warehouse facilities often leased johnson johnson 's properties maintained good operating condition repair well utilized information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements johnson johnson 's annual report shareholders fiscal year segment information additions johnson johnson 's property plant equipment contained johnson johnson 's annual report shareholders fiscal year item legal proceedings information set forth note legal proceedings notes consolidated financial statements johnson johnson 's annual report shareholders fiscal year incorporated herein reference company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws primary relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company item submission matters vote security holders applicable executive officers registrant listed executive officers johnson johnson march unless otherwise indicated employee company affiliates held position indicated past five years family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including following executive officers directors incorporated herein reference pages johnson johnson 's proxy statement dated march table caption name age position c c robert j darretta member board directors member executive committee executive vice president chief financial officer russell c deyo member executive committee vice president administrationa michael j dormer member executive committee worldwide chairman medical devices groupb roger fine member executive committee vice president general counselc colleen goggins member executive committee worldwide chairman consumer personal care groupd joann heffernan heisen member executive committee vice president chief information officere james lenehan vice chairman board directors president member executive committee table table caption name age position c c brian perkins member executive committee worldwide chairman consumer pharmaceuticals nutritionals groupf per peterson md phd member executive committee chairman research development pharmaceuticals groupg christine poon member executive committee worldwide chairman pharmaceuticals grouph william c weldon chairman board directors chief executive officer chairman executive committee robert n wilson senior vice chairman board directorsi table mr r c deyo joined company became associate general counsel became member executive committee vice president administration b mr j dormer joined company company group chairman worldwide franchise chairman depuy codman company acquired depuy inc time acquisition chief operating officer depuy inc since mr dormer served president depuy international ltd mr dormer became member executive committee franchise group chairman medical devices april mr dormer named worldwide chairman medical devices group c mr r fine joined company became member executive committee vice president administration vice president general counsel ms c goggins joined company held various positions becoming president personal products company named president johnson johnson consumer products company company group chairman north america johnson johnson consumer products ms goggins became member executive committee worldwide chairman consumer personal care group e ms j h heisen joined company became treasurer controller became member executive committee vice president chief information officer f mr b perkins joined company held various positions becoming president mcneil consumer products company company group chairman otc pharmaceuticals became member executive committee worldwide chairman consumer pharmaceuticals nutritionals group g dr p peterson joined company vice president drug discovery rw johnson pharmaceutical research institute named group vice president pharmaceutical research institute april president november dr peterson named chairman research development pharmaceuticals group dr peterson became member executive committee h ms c poon joined company company group chairman pharmaceuticals group ms poon became member executive committee worldwide chairman pharmaceuticals group prior joining company served various management positions bristolmyers squibb years recently president international medicines president medical devices mr wilson joined company served several sales marketing management positions appointed company group chairman appointed executive committee appointed chairman sector operating committee appointed vice chairman board directors assumed expanded responsibilities vice chairman executive committee named senior vice chairman board directors part ii item market registrant 's common equity related shareholder mattersthe information called item incorporated herein reference material captioned management 's discussion analysis results operations financial condition share repurchases dividends common stock market prices johnson johnson 's annual report shareholders fiscal year item selected financial data information called item incorporated herein reference material captioned summary operations statistical data johnson johnson 's annual report shareholders fiscal year item management 's discussion analysis financial condition results operations information called item incorporated herein reference narrative tabular graphic material included material captioned management 's discussion analysis results operations financial condition pages johnson johnson 's annual report shareholders fiscal year item quantitative qualitative disclosures market risk information called item incorporated herein reference material captioned management 's discussion analysis results operations financial condition financial position capital resources johnson johnson 's annual report shareholders fiscal year item financial statements supplementary data information called item incorporated herein reference consolidated financial statements notes thereto material captioned independent auditor 's report pages johnson johnson 's annual report shareholders fiscal year item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information called item incorporated herein reference material caption election directors nominees pages johnson johnson 's proxy statement dated march b material part hereof caption executive officers registrant c material caption section beneficial ownership reporting compliance johnson johnson 's proxy statement dated march item executive compensation information called item incorporated herein reference following sections johnson johnson 's proxy statement dated march election directors directors ' fees committees meetings pages compensation committee report executive compensation pages shareowner return performance graphs pages executive compensation pages item security ownership certain beneficial owners management information called item incorporated herein reference material captioned election directors stock ownershipcontrol pages johnson johnson 's proxy statement dated march item certain relationships related transactions applicable item controls procedures disclosure controls within days filing report company evaluated effectiveness design operation disclosure controls procedures company 's disclosure controls procedures arethe controls procedures company designed ensure records processes summarizes reports timely manner information company must disclose reports filed securities exchange act william c weldon chairman chief executive officer robert j darretta executive vice president chief financial officer reviewed participated evaluation based evaluation messrs weldon darretta concluded date evaluation company 's disclosure controls procedures effective internal controls since date evaluation described significant changes company 's internal controls factors could significantly affect controls including corrective actions regard significant deficiencies material weaknesses part iv item exhibits financial statement schedules reports form k following documents filed part report financial statements following consolidated financial statements notes thereto independent auditor 's report pages johnson johnson 's annual report shareholders fiscal year incorporated herein reference consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements independent auditor 's report financial statement schedules schedule ii valuation qualifying accounts schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report b reports form k report form k filed october included press release statement amgen arbitration report form k filed december included press release statement change european labeling eprexerypo report form k filed december regarding funding company 's us pension plan report form k filed january included press release statement amgen arbitration also reported resignation john w snow board directors report form k filed march included management 's discussion analysis financial condition results operations independent auditors ' report johnson johnson subsidiaries schedule ii valuation qualifying accountsfiscal years ended december december december dollars millions table caption additions balance charged deductions reserves balance beginning costs end period expensesa description amount period c c c c c reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments reserves deducted accounts receivable trade reserve doubtful accounts writeoffs less recoveries currency adjustments reserve customer rebates customer rebates allowed currency adjustments reserve cash discounts cash discounts allowed currency adjustments table charges related customer rebates cash discounts reflected reductions sales customers signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date march johnson johnson registrant w c weldon w c weldon chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated table caption signature title date c c w c weldon chairman board directors march chief executive officer w c weldon director principal executive officer r j darretta executive vice president chief march financial officer director r j darretta principal financial officer j cosgrove controller march j cosgrove g n burrow director march g n burrow j g cullen director march j g cullen director march j folkman jordan director march jordan g langbo director march g langbo jt lenehan vice chairman board directors march president director jt lenehan table table caption signature title date c c lf mullin director march lf mullin satcher director march satcher h b schacht director march h b schacht f singer director march f singer r n wilson senior vice chairman board march directors director r n wilson table certification chief executive officer pursuant rule securities exchange act william c weldon certify reviewed annual report johnson johnson registrant based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent function significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses william c weldon william c weldon chief executive officer date march certification chief financial officer pursuant rule securities exchange act robert j darretta certify reviewed annual report johnson johnson registrant based knowledge annual report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered annual report based knowledge financial statements financial information included annual report fairly present material respects financial condition results operations cash flows registrant periods presented annual report registrant 's certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules registrant designed disclosure controls procedures ensure material information relating registrant including consolidated subsidiaries made known us others within entities particularly period annual report prepared b evaluated effectiveness registrant 's disclosure controls procedures date within days prior filing date annual report evaluation date c presented annual report conclusions effectiveness disclosure controls procedures based evaluation evaluation date registrant 's certifying officers disclosed based recent evaluation registrant 's auditors audit committee registrant 's board directors persons performing equivalent function significant deficiencies design operation internal controls could adversely affect registrant 's ability record process summarize report financial data identified registrant 's auditors material weaknesses internal controls b fraud whether material involves management employees significant role registrant 's internal controls registrant 's certifying officers indicated annual report whether significant changes internal controls factors could significantly affect internal controls subsequent date recent evaluation including corrective actions regard significant deficiencies material weaknesses robert j darretta robert j darretta chief financial officer date march certification chief executive officer pursuant usc section undersigned william c weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies company 's annual report fiscal year ended december report fully complies requirements ofsection securities exchange act information contained report fairly presents material respects financial condition results operations company william c weldon william c weldon chief executive officer dated march certification accompanies report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended certification chief financial officer pursuant usc section undersigned robert j darretta chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company robert j darretta robert j darretta chief financial officer dated march certification accompanies report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended report independent accountants financial statement schedule shareholders board directors johnson johnson audits consolidated financial statements referred report dated january except note date february appearing annual report shareholders johnson johnson report consolidated financial statements incorporated reference annual report also included audit financial statement schedule listed item opinion financial statement schedule presents fairly material respects information set forth therein read conjunction related consolidated financial statements pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york january exhibit index tablecaption reg sk exhibit table description item exhibit c ai restated certificate incorporation dated april incorporated herein reference exhibit registrant 's annual report year ended december aii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit registrant 's annual report year ended january aiii certificate amendment restated certificate incorporation company dated may incorporated herein reference exhibit aiii registrant 's annual report year ended december aiv certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july b bylaws company amended effective june incorporated herein reference exhibit registrant 's form q quarterly report quarter ended july upon request securities exchange commission registrant furnish copy instruments defining rights holders long term debt registrant stock option plan nonemployee directors incorporated herein reference exhibit registrant 's annual report year ended december b stock option plan amended filed document c stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended january stock option plan amended incorporated herein reference exhibit c registrant 's annual report year ended december e stock compensation plan incorporated herein reference exhibit e registrant 's annual report year ended december f executive incentive plan amended incorporated herein reference exhibit f registrant 's annual report year ended december g domestic deferred compensation certificate extra compensation plan amended incorporated herein reference exhibit g registrant 's annual report year ended december h deferred fee plan directors amended filed document executive income deferral plan amended filed document j excess savings plan incorporated herein reference exhibit j registrant 's annual report year ended december k supplemental retirement plan incorporated herein reference exhibit h registrant 's annual report year ended january l executive life insurance plan incorporated herein reference exhibit registrant 's annual report year ended january stock option gain deferral plan incorporated herein reference exhibit registrant 's annual report year ended january n estate preservation plan incorporated herein reference exhibit n registrant 's annual report year ended january table table captionreg sk exhibit table description item exhibit c letter agreement dated june company mr r larsen respect postemployment arrangements filed document p consulting agreement company dr judah folkman member board filed document statement computation ratio earnings fixed charges filed document pages company 's annual report shareholders fiscal year portions annual report incorporated reference report deemed filed filed document subsidiaries filed document consent independent accountants filed document annual reports form k johnson johnson savings plans filed june b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document table management contracts compensatory plans arrangements required filed exhibits form pursuant item c report copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company text document document typeexb sequence filenameyexvwbtxt description stock option plan amended text exhibit b johnson johnson stock option plan amended february purpose purpose johnson johnson stock option plan plan promote interests johnson johnson company ensuring continuity management increased incentive part officers executive employees responsible major contributions effective management facilitating acquisition equity interest company reasonable terms administration plan shall administered compensation committee board directors committee committee shall consist less three directors person shall eligible continue serve member committee unless person nonemployee director within meaning rule b general rules regulations securities exchange act amended outside director within meaning section internal revenue code amended internal revenue code committee shall power select optionees establish number shares terms applicable option construe provisions plan adopt rules regulations governing administration plan board directors within discretion shall authority amend plan terms option issued hereunder without necessity obtaining approval shareowners unless approval required law notwithstanding foregoing except stock split adjustment orother change corporate structure shares company contemplated section av hereof company shall neither lower exercise price option granted plan grant option hereunder replacement option previously granted higher exercise price without approval shareowners eligibility eligible participate plan selected committee following directors officers key employees company domestic subsidiaries key employees subsidiaries outside united states key employees joint venture operation company subsidiaries key employees joint venture partners assigned joint venture cases optionees shall selected basis demonstrated ability contribute substantially effective management financial performance company subsidiaries event shall option granted individual immediately option granted considered stock possessing combined voting power classes stock johnson johnson subsidiaries within meaning section internal revenue code allotment shares amount common stock company par value per share may made subject grants options plan calendar year shall exceed amount equal percent issued shares company 's common stock including treasury shares january year plus number shares available grants previous year plan made subject grant previous year ii number shares covered options granted plan options lapsed expired terminated previous year without exercised notwithstanding foregoing million shares aggregate shall available issuance incentive stock options plan total number shares may awarded plan optionee one year shall exceed lesser x total shares allotted plan year million shares committee may discretion issue upon exercise option treasury shares authorized unissued shares effective date term plan plan approved shareowners company shall become effective april option shall granted pursuant plan later april rights optionees options theretofore granted affected unexpired options continue force operation thereafter except options may lapse terminated accordance terms conditions terms conditions aall options following shall apply options granted plan option price option price per share stock option shall determined committee shall less fair market value date option granted fair market value shall determined prescribed internal revenue code regulations ii time exercise option committee shall establish time times within option period stock option may exercised whole parts may specified time time committee respect optionee whose employment terminated reason death disability retirement committee may discretion accelerate time times particular stock option held said optionee may exercised time times earlier originally provided said option cases exercise stock option shall subject provisions section bii ciii case may committee shall determine either time grant later whether extent circumstances delivery shares issuable connection exercise nonqualified option may deferred election optionee iii payment entire option price may paid time option exercised option exercised prior termination employment committee shall discretion arrange payment price whole part installments cases committee shall obtain evidence optionee 's obligation establish interest rate require security may deem appropriate adequate protection company iv nontransferability option unless otherwise specified committee contrary option terms shall transferable optionee otherwise laws descent distribution shall exercisable optionee 's lifetime optionee committee may manner established committee provide transfer without payment consideration nonqualified option optionee member optionee 's immediate family trust partnership whose beneficiaries members optionee 's immediate family case option shall exercisable transferee purposes provision optionee 's immediate family shall mean holder 's spouse children grandchildren v adjustment event recapitalization company event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company board directors shall make adjustment may deem equitably required number kind shares authorized plan number kind shares covered options granted number shares may awarded optionee one year option price vi rights termination employment event termination employment due cause death disability retirement rights exercise stock option shall cease except accrued including date termination defined unless committee shall otherwise specify rights shall remain exercisable period three months date termination longer period exceed three years committee shall provide event termination employment due death disability rights exercise stock option shall cease except accrued including date termination unless committee shall otherwise specify rights shall remain exercisable period three years longer period exceed term option committee shall provide notwithstanding event termination employment due death disability occurs optionee least ten years service unexercised unexercisable portion stock option may exercised whole part remaining term option times extent optionee could exercised stock option optionee 's employment terminated event retirement unrelated termination cause defined shall governed provisions rights exercise stock option shall cease except accrued including date termination unless committee shall otherwise specify rights shall remain exercisable aperiod three years longer period exceed term option committee shall provide provided however event optionee employed competitor defined within two years date retirement rights may exercisable beyond date three months commencement employment competitor notwithstanding event retirement unrelated termination cause shall governed provisions occurs optionee least ten years service unexercised unexercisable portions stock option may exercised whole part remaining term stock option times extent optionee could exercised stock option optionee 's employment terminated provided however event optionee employed competitor within two years date retirement unexercisable portion stock option shall terminate immediately ii rights may exercisable beyond date three months commencement employment competitor stock option shall event exercised expiration years date option granted earlier date may specified option addition stock option granted within six months termination employment due cause whatsoever shall void unless committee shall otherwise provide used plan term termination cause shall mean optionee 's termination company subsidiaries connection violation federal state law dishonesty willful deliberate failure part optionee perform hisher employment duties material respect events including existence conflict interest management compensation committee may determine committee shall sole discretion determine whether termination cause exists determination shall final ii term employed competitor shall mean optionee 's engaging activity providing services whether director employee advisor consultant otherwise corporation entity competitor company subsidiaries management compensation committee shall sole discretion determine optionee employed competitor determination shall final iii term date termination shall mean last date optionee active employment status specifically event optionee covered severance agreement arrangement date termination shall last day date active employment date corresponding end severance period b nonqualified stock options committee may discretion grant options plan whole part qualify incentive stock options section internal revenue code addition terms conditions set forth section following terms conditions shall govern option portion thereof extent qualify form payment payment option price option portion thereof qualifying incentive stock option shall made cash discretion committee common stock company valued fair market value shall determined committee combination common stock cash payment option price made common stock acquired company compensation plan within meaning opinion accounting principles board common stock accepted payment unless optionee beneficially owned suchcommon stock least six months increased one year common stock acquired incentive stock option prior payment ii period option exercise period nonqualified stock option terms shall l years date option granted specified committee c incentive stock options committee may discretion grant options plan qualify whole part incentive stock options section internal revenue code addition terms conditions set forth section following terms conditions shall govern option portion thereof extent qualifies maximum fair market value incentive stock options aggregate fair market value determined time option granted common stock optionee may stock options first become vested calendar year incentive stock option plans company subsidiaries shall exceed ii form payment payment option price incentive stock options shall made cash common stock company valued fair market value shall determined committee combination common stock cash payment option price made common stock acquired company compensation plan within meaning opinion accounting principles board common stock accepted payment unless optionee beneficially owned common stock least six months increased one year common stock acquired incentive stock option prior payment iii period option exercise period incentive stock option terms shall l years date option granted specified committee options nonemployee directors notwithstanding foregoing event inconsistency terms conditions following terms conditions following terms conditions shall govern stock options granted nonemployee directors board directors committee shall establish time times within option period stock option may exercised whole parts may specified time time committee provided however option shall become exercisable upon completion nonemployee director 's board service ii nonemployee director completes service director company reason death options may exercised time remainder option term iii event nonemployee director 's death regardless whether still serving director option may exercised subject provisions section b ii within three years death estate person acquires option inheritance devise thereafter rights shall lapse text document document typeexh sequence filenameyexvwhtxt descriptiondeferred fee plan directors amended text exhibit h johnson johnson deferred fee plan directors amended december purpose purpose johnson johnson deferred fee plan directors plan provide outside directors johnson johnson company opportunity defer receipt compensation earned director date following termination service provision opportunity designed aid company attracting retaining members board directors persons whose abilities experience judgment contribute well company effective date original effective date plan january plan amended entirety effective january december eligibility director company also employee company related company shall participate plan deferred compensation account deferred compensation account shall established director amount deferral participant shall effective january required defer receipt twenty thousand dollars hisher annual fee serving board directors required deferral addition participant may elect defer receipt specified part remaining compensation payable participant serving board directors serving committees board directors company amount equal deferred compensation credited participant 's deferred compensation account quarterly basis dividend payment date quarter payment date event shall dividend payment date quarter payment date shall deemed last business day quarter deferred compensation account hypothetical investment options required deferrals unless otherwise specified participant pursuant terms paragraph b section amounts elected deferred plan calendar year shall credited participant 's deferred compensation account converted equivalent units johnson johnson common stock company stock adjusted compensation deferred invested company stock payment date date final payment pursuant section hereof company stock equivalent units number company stock equivalent units shall determined dividing amount compensation payable average high low price company stock traded new york stock exchange trading day immediately prior payment date reported bloomberg another financial reporting service selected company sole discretion number company stock equivalent units included participant 's deferred compensation account shall adjusted reflect dividends value account shall adjusted reflect increases decreases market value would resulted funds equal balance participant 's deferred compensation account invested company stock nothing herein obligates company purchase company stock company stock purchased shall remain sole property company b except respect required deferral amount election participant made provided section deferred compensation account credited interest payment date date final payment pursuant section hereof rate equal annual rate growth investment johnson johnson certificate extra compensation plan cec plan prior year provided however computation said growth rate shall include dividend equivalents paid cec plan election permitted section b shall available participant becomes participant plan december c respect company stock equivalent units deferred compensation account company shall credit account dividend payment date declared respect company 's stock number company stock equivalent units equal product dividend per share company 's stock payable dividend payment date multiplied z number company stock equivalent units credited account applicable dividend record date divided ii averageof high low price company stock traded new york stock exchange trading day immediately prior dividend payment date reported bloomberg another financial reporting service selected company sole discretion fractional company stock equivalent units shall carried forward fractional dividend equivalent units shall payable thereon account balances company stock equivalent units company 's retirement plan nonemployee directors transferred hisher deferred compensation account plan january reason termination retirement plan shall treated purposes plan required deferrals time election deferral except required deferrals shall times held company stock equivalent units participant may change amount compensation deferred andor ii option elected section respect hisher account deferrals subsequent years annually december completing forms provided company purpose change shall become effective january following year participant elects change hisher investment option available section participant 's account shall valued december value entered hisher account new investment option following january except change company stock equivalent units first trading day following january shall used value deferred compensation account value participant 's deferred compensation account shall case may include compensation deferred interest credited thereon adjustments dividends increases decreases market value company stock pursuant option selected section otherwise required plan company stock trade date calculation common stock equivalent units made plan next preceding date stock traded shall utilized payment deferred compensation upon participant 's completion service member board directors completion date participant event participant 's death named beneficiary hisher estate shall entitled receive cash lump sum value hisher deferred compensation account completion date unless participant elected pursuant provisions section defer payment hisher deferred compensation account beyond completion date company stock equivalent units shall valued average high low price company 's stock traded new york stock exchange trading day immediately prior date reported bloomberg another financial reporting service selected company sole discretion withdrawal may made participant 's deferred compensation account prior completion date value participant 's deferred compensation account shall subject election made pursuant section paid soon practicable following completion date death deferral election addition deferral elections referred participant may also elect manner provided continue defer receipt hisher deferred compensation account beyond hisher completion date value participant 's account hisher completion date may deferred taxable years following completion date installments elected first installment payment may made immediately completion date deferred taxable years installment payments made annually manner described approximately equal amounts ie balance account minimum number installments two maximum number provided however payments shall made within ten years completion date participant may elect defer value hisher account completion date percentage increment less deferred installment payments shall made cash following additional rules shall apply immediate lump sum payment participant receive full value hisher account calendar month hisher completion date b deferred lump sum payment participant receive full value hisher account january year heshe elects receive payment c immediate commencement installments participant receive first installment calendar month hisher completion date subsequent installments january year deferred commencement installments participant receivethe first subsequent installments january year e event death participant company make payment full balance account soon administratively practical single lump sum payment designated beneficiary hisher estate f making payment due january value participant 's account first trading day month shall utilized deferrals following completion date shall invested company stock equivalent units described section extent participant 's account credited annual growth rate investment cec plan described section b account shall converted common stock equivalent units completion date election participant defer payment elect installments part hisher deferred compensation account beyond completion date must made minimum twelve months prior completion date election may revised revoked twelve months prior completion date time election may revoked otherwise revised notwithstanding upon implementation plan exception made participants completion date participants deferral installment election must made minimum three months calendar year prior completion date example participant completion date april must make deferral andor installment election later december election defer andor receive installment payments may revised revoked prior last permissible date making election time election may revoked otherwise revised election defer payment andor paid installments beyond completion date effective filed extra compensation services form utilized purposes election made required deadline shall disregarded designation beneficiary participant may time time writing filed secretary company designate legal natural person persons may designated contingently successively payments participant 's deferred compensation account made participant dies prior receipt payment account beneficiary designation effective signed form filed secretary company participant alive cancel beneficiary designation forms filed earlier participant fails designate beneficiary provided designated beneficiaries die participant complete payment deferred compensation account account shall paid estate last die participant designated beneficiaries soon practicable death participant 's rights unsecured right participant receive payment provisions plan shall unsecured claim general assets company provisions contained plan shall construed give participant beneficiary time security interest deferred compensation account asset trust company benefit participant beneficiary statement account statement sent participants soon practical following end year value hisher deferred compensation account december year assignability right receive payments hereunder shall transferable assignable participant beneficiary except laws descent distribution administration plan plan shall administered committee appointed responsible board directors committee shall consist less three directors company committee shall act vote written consent majority members amendment termination plan plan may time time time amended modified terminated compensation committee board directors board directors company amendment modification termination shall without consent participant adversely affect participant 's accruals deferred compensation accounts governing law agreement shall governed construed accordance laws state new jersey text document document typeexi sequence filenameyexvwitxt descriptionexecutive income deferral plan amended text exhibit johnson johnson executive income deferral plan amended december johnson johnson executive income deferral plan plan intended permit select group executives defer income would otherwise immediately payable various compensation andor incentive plans johnson johnson company administration plan administered compensation committee company 's board directors committee shall responsibility determining investments time time available plan shall review investment options least every three years committee shall make decisions affecting timing price amount deferred awards hereinafter defined participants subject section securities exchange act amended may otherwise delegate authority plan eligibility eligibility defer income amounts plan initially limited members executive committee company committee may time time expand eligibility defer compensation plan executives company committee however authority refuse permit executive participate plan elect defer payments committee determines participation would jeopardize plan 's compliance applicable law plan 's status top hat plan erisa deferral income deferral account estate preservation plan participants may elect defer fifty percent annual salary ii one hundred percent cash andor stock awards company 's executive incentive plan iii one hundred percent dividend equivalents paid company 's certificate extra compensation cec plan iv one hundred percent dividend equivalents paid deferred gain shares company 's stock option gain deferral plan amounts deferred known deferred awards directed election participant either income deferral account estate preservation plan described participant 's decision defer plan must made september year prior commencement fiscal year compensation bonus incentive payment dividend equivalent monies deferred earned notwithstanding foregoing required notice period elections made respect amounts deferred iv shall governed notice election provisions stock option gain deferral plan election defer pursuant section shall effective timely filed extra compensation services form utilized purpose participant shall designate multiples deferred award portion allocated investment option available plan participant may change investment options deferred awards yet credited income deferral account month change effective first day month following month participant 's request change allocation filed extra compensation services determining maximum amounts deferred participant plan committee shall take account include commitment made participant estate preservation plan extent amount salary andor cash award company 's executive incentive plan insufficient meet prior deferral commitment made participant plan estate preservation plan deferral commitment plan shall reduced accordingly thedeferral commitment estate preservation plan funded full elections defer dividend equivalents company 's cec plan applied elections apply cec contracts reverse order issuance deferred awards shall held one account regardless form compensation plan earned upon ceasing employee company participant event participant 's death named beneficiary hisher estate shall entitled receive cash lump sum value hisher income deferral account date termination unless participant elected pursuant provisions section defer payment hisher income deferral account beyond retirement notwithstanding participant fiscal year named executive officer proxy statement reporting purposes reason hisher chief executive officer company one four highest compensated officers chief executive officer payment income deferral account otherwise due made year shall postponed date th day january following fiscal year provided however funds income deferral account shall deemed invested one year treasury bill rate described date retirement payment made investment income deferral accounts election participant amounts income deferral account may invested utilizing investment options set forth amounts deferred month including stock award valued credited participant 's income deferral account effective last day month amounts deferred estate preservation plan separate distinct amounts deferred income deferral accounts common stock equivalent units amounts elected deferred investment option shall converted equivalent units company 's common stock common stock compensation deferred invested common stock common stock equivalent units number common stock equivalent units shall determined dividing amount compensation dividend equivalents deferred average high low prices common stock traded new york stock exchange trading day immediately preceding last trading day month reported bloomberg another financial reporting service selected company sole discretion company shall credit participant 's income deferral account effective last trading month number full partial shares company 's common stock determined however time shall shares company 's common stock actually purchased earmarked income deferral account participant shall rights shareowner respect shares credited income deferral account number common stock equivalent units included participant 's income deferral account shall adjusted reflect payment dividends increases decreases market value would resulted funds equal deferred amount actually invested common stock value company 's common stock purposes investment redesignation described section shall closing price company 's common stock new york stock exchange trading day immediately preceding last trading day month participant 's redesignation request received extra compensation services reported determined shall effective last trading day month distributions cash value equivalent shares company 's common stock valued closing price company 's common stock new york stock exchange last trading date preceding distribution date reported determined event reorganization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company committee shall make adjustment may deem appropriate number kind shares company 's common stock credited participants ' income deferral accounts b balanced fund amounts elected deferred option shall deemed invested credited investment rate return earned balanced fund option company 's savings plan successor fund however balanced fund shares shall purchased earmarked participant 's accountc one year treasury bill rate amounts elected deferred option shall deemed invested interest bearing account bears interest one year treasury bill rate compounded monthly purposes plan one year treasury bill rate shall interest rate one year treasury bills last trading day preceding calendar year provided financial reporting service shall selected company sole discretion rate shall adjusted annually treasury bills actually purchased earmarked participant 's account redesignation investment options within income deferral account participant may redesignate amounts previously credited income deferral account among investment options available plan participants wish redesignate particular investment option may time redesignate investment option redesignation investments may take place days prior scheduled distribution plan following additional rules shall apply respect redesignation previously credited amounts permitted frequencyredesignation participant may made consecutive twelve month period b amount extent redesignationredesignation participant must multiples investment redesignation made c timingredesignation shall take place effective first day month following month participant 's written redesignation received extra compensation services value company 's common stock purposes investment redesignation shall average high low trading price common stock new york stock exchange reported determined trading day immediately preceding last trading day prior month special rules redesignation common stock equivalent units previously credited income deferral account material nonpublic informationthe committee sole discretion advice counsel time may rescind redesignation common stock equivalent units redesignation made participant time redesignation possession material nonpublic information respect company b committee 's estimation benefited information timing redesignation committee 's determination shall final binding event rescission participant 's income deferral account shall returned status though redesignation occurred notwithstanding committee shall rescind redesignation facts reviewed participant general counsel company designee prior redesignation general counsel designee concluded participant possession material nonpublic information ii participant subject section b securities exchange act may redesignate income deferral account common stock equivalent units applicable window period respect release quarterly annual statements sales earnings company iii redesignation amounts income deferral account shall made common stock equivalent units within six months discretionary opposite way transaction common stock held participant company 's savings plan e estate preservation plan participants may transfer amounts income deferral account balance estate preservation plan accordance terms estate preservation plan however transferred estate preservation plan amounts may transferred back income deferral account distribution income deferral accounts participant 's employment terminated reason including death disability participant eligible retire active service company 's pension plan income deferral account automatically paid lump sum soon administratively feasible month following termination employment distributions cash value equivalent shares company 's common stock valued average high low trading prices common stock new york stock exchange reported determined trading day immediately preceding last trading day month employment wasterminated post retirement deferrals election participant made provided payment sum otherwise due participant upon hisher retirement may deferred paid either single lump sum installments lump sum payment may deferred ten taxable years following participant 's retirement date installment payments elected first installment payment may made immediately upon retirement deferred ten taxable years installment payments made annually manner described approximately equal installment amounts ie value balance income deferral account plus accrued interest divided number remaining installments minimum number annual installments two maximum number fifteen participant may elect defer value hisher total income deferral account retirement percentage increment less payment amounts income deferral account pursuant section shall subject provisions last sentence section following additional rules shall apply respect payments immediate lump sum payment participant receive full value income deferral account calendar month retirement effective date participants retiring prior determination prior years incentive plan award receive estimated value remainder paid shortly final value determined b deferred lump sum payment participant receive full value income deferral account plus accrued interest january year elects receive payment c immediate commencement installments participant receive first installment calendar month hisher retirement effective date subject provisions last sentence section subsequent installments plus accrued interest paid january year deferred commencement installments participant receive first subsequent installments plus accrued interest january year respect amounts deferred andor paid installments interest shall paid company effective date retirement date payment interest rate deferred andor installment payments participant shall fixed date retirement shall rate rounded decimal place offered reported financial reporting service company sole discretion shall select effective retirement date united states treasury instrument period comparable length period deferral andor installment payments interest shall compounded semiannually last calendar day june december year one instrument quoted average rates shall utilized way example election made receive installments eight years comparable eight year us treasury rate shall utilized election made defer commencement installments two years installments paid ten years comparable twelve year us treasury rate shall utilized established interest rate shall remain fixed period deferral andor installments event death participant following retirement company make payment full balance hisher income deferral account plus accrued interest soon administratively practical single lump sum payment designated beneficiary subject provisions last sentence section event deferral installment election made section total amount income deferral account paid accordance provisions section lump sum payment soon practical following participant 's retirement effective date election participant defer payment elect installments part hisher account beyond hisher effective retirement date must made minimum twelve months prior date retirement date election may revised revoked twelve months prior retirement date twelve month period prior retirement date election irrevocable thus may revoked otherwise revisednotwithstanding plan 's inception exception made participants retirement effective date january december participants retirement effective date prior june deferral andor installment election must made minimum three months calendar year prior retirement date participants retirement date july december election must made least six months prior retirement date example participant retires april must make deferral andor installment election later december retirement date august election must made later january election defer andor receive installment payments may revised revoked prior last permissible date making election time election may revoked otherwise revised election defer payment andor paid installments effective timely filed extra compensation services form utilized purpose election made required deadline shall disregarded estate preservation plan described section participant may elect transfer portion balance income deferral account estate preservation plan accordance terms estate preservation plan event election participant 's income deferral account shall reduced directed participant december year transfer occur transfers income deferral account estate preservation plan shall made effective december year transfer shall irrevocable made pursuant terms split dollar life insurance agreement designated compensation committee otherwise upon terms conditions set compensation committee upon election participant transfer amounts income deferral account estate preservation plan participant shall deemed waived irrevocably rights benefits might due plan respect amounts transferred b addition terms set forth paragraph amounts participant 's income deferral account may transferred estate preservation plan order satisfy prior obligation participant connection estate preservation plan transfer shall made solely upon direction compensation committee upon determination compensation committee transfer necessary shall effected terms conditions voluntary transfer paragraph determined committee transfer necessary participant 's income deferral account shall reduced requisite amount december st year directed compensation committee upon determination compensation committee subsequent transfer amounts estate preservation plan participant shall deemed waived irrevocably rights benefits might due plan respect amounts transferred deductions distributions company deduct distribution amounts required withheld income social security tax purposes withholding done pro rata basis per investment company may also deduct amounts participant owes company reason beneficiary designations participant may designate one beneficiaries receive value hisher income deferral account upon death beneficiary predecease participant beneficiary named amount designated beneficiary participant 's balance case may distributed participant 's estate beneficiary designations may made revised time submitting beneficiary designation form extra compensation services amendments committee may amend plan time however amendment shall without consent participant materially adversely affect right obligation respect deferred award made theretofore miscellaneous company fund obligations created participant 's participation plan rather company makes anunsecured promise pay obligations general corporate assets applies obligations active retired participants first quarter calendar year statements sent active participants participating plan well retirees deferral accounts statement also include previously made deferral elections beneficiary designations report retirees provide deferred payout balance plus interest well deferred andor installment election beneficiary designations plan shall administered extra compensation services department corporate headquarters company questions regard administration plan addressed election defer andor paid installments made consultation participant 's tax andor financial advisor text document document typeexo sequence filenameyexvwotxt descriptionletter agreement text exhibit june mr ralph larsen one johnson johnson plaza new brunswick nj postemployment arrangements dear ralph november met compensation committee board directors discuss matters related management succession transition leadership johnson johnson company meeting agreed remain company least april exchange certain arrangements made available following employment company including reimbursement office space furnishings equipment secretarial support access company aircraft meeting compensation committee june compensation committee determined would best interests parties clarify better define document arrangements follows whereas ralph larsen served chairman chief executive officer johnson johnson company april continued continue provide transition management advice mr william c weldon current chairman chief executive officer upon request mr weldon whereas compensation committee recognized based upon leadership company dedication credo values recognized expertise corporate management mr larsen serve retirement ambassador goodwill johnson johnson therefore company mr larsen agree follows mr larsen agrees period five years following retirement company requested chief executive officer company participate various external activities events benefit company mr larsen agrees provide ten days per year company subject reasonable availability participation external activities events mr larsen willing participate external activities events request chief executive officer company fee reimbursement costs expenses wife consideration mr larsen 's dedicated service company continued visibility former chairman board future role ambassador goodwill johnson johnson agreement provide services next five years behalf chief executive officer allof shall serve benefit company shareowners following arrangements shall provided mr larsen 's full benefit furnished office company pay staffed furnished office mr larsen location determined mr larsen office arrangements include appropriate secretarial support computer telecommunications equipment support service office related arrangements commensurate mr larsen 's position former chairman board remain place duration life company aircraft upon mr larsen 's retirement duration life mr larsen entitled hours flying time year company aircraft owned leased including helicopters hours determined based actual flying time mr larsen board aircraft mr larsen priority access company aircraft specific aircraft priority access means mr larsen access company aircraft following individuals holding positions listed annex hereto shall take priority access company aircraft directors officers employees company positions listed annex may modified upon mutual agreement chief executive officer mr larsen reflect changes organizational structure mr larsen provide company reasonable advance notice requests use company aircraft mr larsen may accompanied family members friends using company aircraft taxes arising use company aircraft responsibility mr larsen provision action taken agreement shall affect way mr larsen 's rights company compensation employee benefit pension welfare plans programs agreement unconditional irrevocable shall remain full force effect regardless merger change control ownership sale substantially assets company change modification provision hereof shall binding unless writing signed mr larsen duly authorized representative board directors company foregoing meets approval kindly sign acknowledge agreement terms letter truly william c weldon arnold g langbo william c weldon arnold g langbo chairman chief executive officer chairman compensation committee accepted agreed ralph larsen ralph larsen text document document typeexp sequence filenameyexvwptxt descriptionconsulting agreement text exhibit p consulting agreement agreement judah folkman md individual business address children 's hospital hunnewell longwood avenue boston hereinafter called consultant johnson johnson business address one johnson johnson plaza new brunswick nj hereinafter called jjwitnesseth whereas jj desires engage consultant 's professional services whereas consultant desires render professional services jj whereas consultant represents obligation third party would interfere rendering jj professional services hereinafter defined whereas jj desires engage consultant 's professional services one year period january december subject renewal upon consent parties therefore consideration premises mutual promises covenants herein contained parties hereto agree follows jj hereby offers engage consultant accepts engagement jj consultant 's professional services follows advising attendance participation scientific advisory committee meetings consideration consultant 's acceptance consulting agreement performance professional services specifically set forth paragraph hereof jj shall pay consultant fee three thousand dollars per scientific advisory committee meeting attended starting date last set addition jj agrees reimburse consultant reasonable outofpocket including jjauthorized travel expenses incurred providing consulting services jj hereunder airline expenses generally reimbursed business class level receipts shall required individual expenses exceeding order carry consulting services set forth herein may necessary jj disclose provide consultant certain technical economic scientific andor business information relating research development activities interests jj affiliates hereinafter collectively referred information jj considers proprietary additionally certain technical economic scientific andor business information may developed consultant course services provided jj hereunder information also included term information consultant agrees keep information strict confidence disclose use information purpose performance services contemplated herein without prior written consent jj inventions whether patentable improvements ideas information made conceived connection performance services hereunder shall exclusive property jj consultant without charge jj shall execute acknowledge deliver jj papers including assignments applications patents may necessary enable jj publish protect said inventions improvements ideas patent otherwise countries vest title said patents inventions improvements ideas jj nominees successors assigns shall render assistance jj may require patent office proceeding litigation involving said inventions improvements ideas information copyrightable work created consultant connection performance services contemplated agreement shall considered work made hire whether published unpublished rights therein shall property jj employer author owner copyright work consultant without charge jj reasonable payment time involved event services contained agreement shall terminated jj 's expense shall duly execute acknowledge deliver jj papers including assignments applications copyright registration renewal may necessary enable jj publish protect said works copyright otherwise countries vest title said work jj nominees successors assigns shall render assistance jj may require proceeding litigation involving rights said works jj reserves right time upon written notice consultant terminate agreement event jj shall obligated pay consultant services provided prior termination consultant agrees promptly inform jj occurrence would affect ability consult jj hereunder includes similar agreements pharmaceutical companies research organizations consultant represents obligation agreement third party would prevent carrying duties obligations agreement consultant agrees originate use name jj employees publicity news release public announcement written oral whether public press otherwise relating consulting agreement amendment hereto performance hereunder without prior written consent jj consultant agrees matters arising consulting agreement shall interpreted laws state new jersey united states america venue deciding disputes hereunder shall state new jersey consultant understands agrees relationship jj hereunder independent contractor employee agent jj entitled participate benefits privileges available jj employees unless otherwise provided herein terminated pursuant paragraph term agreement shall one year last date set forth december agreement shall renewable successive one year periods upon mutual written consent parties notwithstanding termination agreement rights obligations recited paragraphs shall continue witness whereof parties hereto caused agreement duly executed day year signed dated december text document document typeex sequence filenameyexvtxt descriptionstatement computation ratio earnings text exhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions table caption fiscal year ended december december december january january c c c c c determination earnings earnings provision taxes income fixed charges total earnings defined fixed charges rents interests fixed charges capitalized interest total fixed charges ratio earnings fixed charges table ratio earnings fixed charges represents historical ratio johnson johnson calculated total enterprise basis ratio computed dividing sum earnings provision taxes fixed charges excluding capitalized interest fixed charges fixed charges represent interest including capitalized interest amortization debt discount expense interest factor rentals consisting appropriate interest factor operating leases text document document typeex sequence filenameyexvtxt descriptionpages annual report shareholders text exhibit management 's discussion analysis results operations financial condition overview record sales billion exceeded sales billion marked th year consecutive positive sales growth growth led strong performances pharmaceutical medical devices diagnostics segments balance sheet remains strong cash generated operations billion cash dividends per share paid shareholders increased represented th consecutive year cash dividend increases company continues one companies triple credit rating organization management 's objectives company 's objective achieve superior levels capital efficient profitable growth accomplish company 's management operates business consistent certain strategic principles proven successful time end company participates growth areas human health care committed attaining leadership positions growth segments development innovative products services approximately billion sales invested research development recognizing importance ongoing development new differentiated products services company 's system management operates decentralized basis operating companies located countries company views management philosophy asset fundamental success broadly based business also fosters entrepreneurial spirit combining extensive resources large organization ability react quickly local market changes challenges businesses managed long term order sustain leadership positions achieve growth provides enduring source value shareholders unifying management team company 's dedicated employees achieving objectives johnson johnson credo credo provides common set values serves constant reminder company 's responsibilities customers employees communities shareholders company believes basic principles along overall mission improving quality life people everywhere enable johnson johnson continue among leaders health care industry result corporate governance issues certain companies government lawmakers enacted sarbanesoxley act protect investors improving accuracy reliability corporate disclosures light legislation company established documented formal process around already existing internal controls like annual certification compliance management policy business conduct company continues evaluate enhance internal control processes additionally company continues maintain strong ethical environment using johnson johnson credo overall guidedescription business company approximately employees worldwide engaged manufacture sale broad range products health care field company sells products virtually countries world company 's primary interest historically currently products related human health wellbeing company organized principle decentralized management executive committee johnson johnson principal management group responsible operations allocation resources company committee oversees coordinates activities domestic international companies span consumer pharmaceutical medical devices diagnostics segments international subsidiary exceptions managed citizens country located product lines company competes companies large small located united states america abroad competition strong lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important company 's success areas business competitive environment requires substantial investments continuing research multiple sales forces addition winning retention customer acceptance company 's consumer products involves heavy expenditures advertising promotion description segments consumer consumer segment 's principal products personal care including nonprescription drugs adult skin hair care products baby care products oral care products first aid products women 's health products nutritional products products marketed principally general public distributed wholesalers directly independent chain retail outlets throughout world major brands skin hair care line products include neutrogena roc aveeno clean clear johnson 's ph piz buin sundown sun care products shower shower personal care products major brands overthecounter line products include broad family tylenol acetaminophen products adult children 's motrin analgesic products imodium mylanta pepcid acid controller johnson johnson merck consumer pharmaceuticals co major brands women 's health care line products include carefree stayfree ob tampons monistat major brands baby care line products include johnson 's baby line products penaten natusan baby care products major first aid products include bandaid brand adhesive bandages compeed major oral care products include reach brand toothbrushes major products nutritionals product line include splenda noncaloric sugar substitute viactiv calcium chews benecol food products pharmaceutical pharmaceutical segment 's principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology fields products distributed directly wholesalers health care professionals use prescription general public prescription drugs antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarintm miconazole nitrate antifungal products prescription drugs antiinfective field include floxin ofloxacin levaquin levofloxacin prescription drugs cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drugs contraceptive field include ortho evra norelgestrominethinyl estradiol transdermal system orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sold us ortho tricyclen group oral contraceptives prescription drugs dermatology field include retina micro tretinoin dermatological cream acne prescription drugs gastrointestinal field include aciphex rabeprazole sodium proton pump inhibitor treating erosive gastroesophageal reflux disease gerd duodenal ulcers whichthe company derives service revenue product co promoted us eisai imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn 's disease patients remicade also indicated treatment rheumatoid arthritis prescription drugs hematology field include procrit epoetin alfa sold outside us eprex biotechnology derived version human hormone erythropoietin stimulates red blood cell production prescription drugs immunology field include orthoclone okt muromonabcd reversing rejection kidney heart liver transplants prescription drugs neurology field include topamax topiramate reminyl galantamine stugeron cinnarizine prescription drugs oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drugs psychotropic central nervous system field include antipsychotic drugs risperdal risperidone haldol haloperidol concerta methylphenidate attention deficithyperactivity disorder prescription drugs pain management field include duragesic fentanyl transdermal system sold abroad durogesic transdermal patch chronic pain ultracettm tramadol hydrochloride analgesic moderate moderately severe pain prescription drugs urology field include ditropan xl oxybutynin treatment overactive bladder medical devices diagnostics medical devices diagnostics segment includes broad range products used direction health care professionals products include ethicon 's wound care surgical sports medicine women 's health products ethicon endosurgery 's minimally invasive surgical products cordis ' circulatory disease management products lifescan 's blood glucose monitoring products orthoclinical diagnostics ' professional diagnostic products depuy 's orthopaedic joint reconstruction spinal products vistakon 's disposable contact lenses products used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics acquisitions medical devices diagnostics segment recent years integral part ongoing process transform medical supply business one serving range higher technology medical specialties operating results sales worldwide sales increased billion compared increases sales three largest distributors amerisourcebergen corp mckesson hboc cardinal distribution accounted respectively total revenues excluding impact foreign currencies worldwide sales increased price increases accounted approximately growth respectively sales domestic companies billion billion billion represents increases sales international companies billion billion billion represents increases excluding impact foreign currency fluctuations past three years sales international companies increased last five years annual compound growth rate sales excluding impact foreign currency fluctuations annual compound growth rate sales year period geographic areas throughout world posted operational gains excluding effect exchange rate fluctuations us dollar foreign currencies sales increased europe western hemisphere excluding us asiapacific africa regions including impact currency fluctuations sales increased europe asiapacific africa decreased western hemisphere excluding us company achieved annual compound growth rate worldwide sales year period since domestic sales growing rate international sales growing rate excluding impact foreign currency fluctuations annual compound growth rate year period consumer segment sales billion increase increase consumer segment sales prior year operational growth currency negatively impacting sales growth domestic sales increased international sales gains localcurrency offset negative currency impact resulting total international growth consumer sales achieved strong growth skin care products neutrogena clean clear aveeno bandaid wound care products well mcneil nutritionals ' splenda sweetener products viactiv calcium chews consumer segment sales billion increase domestic sales increased international sales gains local currency offset negative currency impact resulting total growth consumer segment sales billion increase domestic sales increased international sales gains local currency offset negative currency impact resulting total decrease pharmaceutical segment sales billion increase including growth domestic sales total growth international sales includes positive effect currency increase pharmaceutical segment sales prior year due operational increases currency positively impacting sales growth sales growth reflects strong performance procriteprex treatment anemia remicade treatment rheumatoid arthritis crohn 's disease risperdal antipsychotic medication duragesic transdermal patch chronic pain topamax antiepileptic medication sales procriteprex accounted total company revenues johnson johnson markets prescription drugs around world sales generated outside united states thirtythree drugs sold company sales excess million excess million rate growth sales procrit eprex slowed latter half result new competition procrit sales growth may also affected rare reports pure red cell aplasia prca chronic renal failure crf patients administered eprex subcutaneously company 's ongoing investigation prca crf patients indicates occurrence prca continues rare second quarter company completed acquisition tibotecvirco nv approximately million tibotecvirco nv privatelyheld biopharmaceutical company focused developing antiviral treatments several promising compounds development treatment infectious diseases including hiv fourth quarter company received us food drug administration fda approval levaquin levofloxacin additional indication treatment nosocomial pneumonia second common hospitalacquired infection company also filed several new drug applications fda include topamax topiramate prevention migraine headaches adults well use monotherapy treatment epilepsy currently approved adjunctive treatment levaquin fiveday treatment communityacquired pneumonia risperdal risperidone adjunctive monotherapy treatments bipolar disorder also fourth quarter company announced definitive agreement acquire orapharma inc specialty pharmaceutical company focused development commercialization unique therapeutics oral health care products acquisition provide entry oral health professional marketplace providing synergistic line prevention treatment products maintain periodontal health transaction valued approximately million net cash closed first quarter pharmaceutical segment sales billion total increase including growth domestic sales operationally international sales increased partially offset negative currency impact resulting total growth pharmaceutical segment sales billion increase including growth domestic sales operationally international sales increased offset negative currency impact resulting total decrease sales sales growth partially offset restricted access propulsid number markets around world worldwide sales billion medical devices diagnostics segment represented increase currency impact sales growth total increase also operational sales increase prior year domestic sales international sales increased prior year strong sales growth achieved major franchises within segment cordis ' circulatory disease management products depuy 's orthopaedicjoint reconstruction spinal products ethicon 's wound care surgical sports medicine women 's health products lifescan 's blood glucose monitoring products ethicon endosurgery 's minimally invasive surgical products orthoclinical diagnostics ' professional diagnostic products vistakon 's disposable contact lenses third quarter company announced final results sirius landmark us study cyphertm sirolimuseluting stent drugeluting coronary stent first kind recommended fda approval clinical results cyphertm stent indicate significant reduction instent restenosis revascularization rates compared bare metal stents findings confirm stent 's continued excellent performance significantly reducing reblockage coronary arteries patients coronary artery disease additionally july us department health human services hhs made decision provide accelerated incremental reimbursement hospitals technology commencing april newly established diagnostic related groups drgs order ensure access technology patients rapidly possible hhs taken unprecedented step assigning new drgs prior fda approval october circulatory system device panel advisory panel voted favor fda approval recommended conditions company 's drugeluting coronary stent company continuing work fda ongoing review product approval also fourth quarter fda 's orthopaedic rehabilitation devices panel unanimously recommended favor fda approval conditions independencetm ibottm mobility system ibottm mobility system unique device offers benefits individuals mobilityrelated disabilities device used navigate difficult terrain climb stairs ramps balance standing height two wheels december ethicon received fda clearance market vicryl plus antibacterial suture first suture designed antibacterial agent designed reduce bacterial colonization suture vicryl plus may help reduce risk complications associated surgery worldwide sales billion medical devices diagnostics segment represented total increase domestic sales international sales increased sales gains local currency offset negative currency impact worldwide sales billion medical devices diagnostics segment represented total increase consisting gains local currency reduced due strength us dollar domestic sales international sales increased sales gains local currency offset negative currency impact gross profit gross profit margin improvement gross profit margin improvement gross profit margin gross profit margin improvement improvement gross profit margin past three years primarily result continued improvements mix businesses successful ongoing cost control efforts selling general administrative expenses consolidated selling general administrative expenses increased respectively selling general administrative expenses percent sales respectively result implementation emerging issues task force eitf issue accounting consideration given vendor customer reseller vendor 's products company reclassified million million respectively selling general administrative expenses reduction sales reclassified million million expense respectively selling general administrative expenses cost products sold advertising expenses comprised television radio print media well internet advertising billion billion billion research expenses research activities represent significant part company 's businessthese expenditures relate development new products improvement existing products technical support products compliance governmental regulations protection consumers patients worldwide costs research activities excluding inprocess research development charges follows table caption millions dollars c c c research expense percent increase prior year percent sales table research expense percent sales pharmaceutical segment averaging consumer medical devices diagnostics segments respectively significant research activities continued pharmaceutical segment spending increasing billion representing compound annual growth rate approximately fiveyear period since johnson johnson pharmaceutical research development llc formerly known janssen research foundation rw johnson pharmaceutical research institute primary worldwide pharmaceutical research organization additional research conducted centocor alza corporation alza tibotecvirco nv collaboration james black foundation london england inprocess research development second quarter company recorded inprocess research development iprd charges million aftertax million tax iprd generally tax deductible us related acquisitions acquisitions included tibotecvirco nv privatelyheld biopharmaceutical company focused developing antiviral treatments obtech medical ag privatelyheld company markets adjustable gastric band treatment morbid obesity fourth quarter iprd charge million aftertax million tax iprd generally tax deductible us incurred result acquisition inverness medical technology supplier lifescan electrochemical products blood glucose monitoring following spinoff nondiabetes businesses teramed early stage medical device company developing endovascular stentgraft systems minimally invasive treatment abdominal aortic aneurysms peripheral occlusive disease company 's iprd charges million aftertax million tax iprd generally tax deductible us related acquisition atrionix inc development stage company whose primary product pulmonary ablation catheter treatment atrial fibrillation crescendo company formed alza purpose selecting developing commercializing human pharmaceutical products interest income expense interest income decreased primarily due decline us interest rates cash expended part stock repurchase program see average yield investments basis points average yield interest expense compared remained relatively constant significant changes average debt balances income expense net income expense includes gains losses related sale writedown certain equity securities johnson johnson development corporation losses disposal fixed assets currency gains losses minority interests litigation settlement expense well royalty income additionally income expense included gain sale ortho prefest product line impact amgen arbitration settlementon october arbitrator chicago denied effort amgen inc terminate license agreement ortho biotech obtained exclusive us rights amgendeveloped erythropoietin epo sold procriteprex indications outside kidney dialysis amgen filed suit claiming ortho biotech breached license rights improperly making sales epo amgen 's exclusive dialysis market decision arbitrator found sales made markets amgen retained exclusive rights warrant extraordinary remedy terminating contract instead found amgen could adequately compensated monetary damages arbitrator awarded million damages recorded third quarter arbitration fourth parties since january arbitrator ruled amgen prevailing party arbitration entitling award reasonable attorneys ' fees costs amgen yet submitted application fees costs company expensed million fourth quarter connection outstanding claim addition items indicated income expense included costs related merger alza million amortization expense approximately million longer required financial accounting standards board fasb standard goodwill intangible assets sfas addition items indicated income expense included favorable adjustment costs associated global manufacturing restructuring charge gain sale various product lines earnings provision taxes income consolidated earnings provision taxes income increased respectively excluding iprd merger charges noted previous sections increases respectively increase due primarily volume growth improved gross profit margins efficiencies spending selling marketing administrative expenses operating profit segment follows table caption percent sales millions dollars c c c c consumer pharmaceutical med devices diag segments total expenses allocated segments earnings taxes income table increase expenses allocated segments primarily due decline interest income discussed interest income expense section consumer segment operating profit increased prior year reflects operating profit percent sales improvement improvement due primarily leveraging selling promotion administrative expenses offset increased expenditures advertising additionally consumer segment operating profit improved amortization expense longer required sfas pharmaceutical segment operating profit increased reflects operating profit percent sales improvement pharmaceutical segment operating profit negatively impacted cost amgen arbitration settlement million damages million legal fees iprd related tibotecvirco nv acquisition offset gain sale ortho prefest product line impact sfas operating profit percent sales pharmaceutical segment pharmaceutical segment operating profit also included effect leveraging marketing expenses pharmaceutical operating profitincluded expenses related merger alza medical devices diagnostics segment operating profit increased reflects operating profit percent sales improvement nonamortization per sfas accounted improvement remaining margin improvement prior year achieved despite investment spending support cordis product line operating profit includes iprd associated acquisitions obtech medical ag inverness medical technology teramed provision taxes income worldwide effective income tax rate increase effective tax rate years primarily due increase income subject tax us company 's nondeductible iprd charge refer footnote financial statements additional information net income earnings per share worldwide net earnings billion reflecting increase worldwide net earnings per share equaled per share increase net earnings per share excluding impact iprd impact iprd merger costs worldwide net earnings billion net earnings per share representing increase respectively impact nonamortization per sfas increased net earnings earnings per share approximately worldwide net earnings achieved year annual growth rate earnings per share grew rate excluding impact accounting change iprd worldwide net earnings achieved year annual growth rate earnings per share grew rate year annual compound growth rates net earnings earnings per share respectively excluding impact iprd merger costs worldwide net earnings achieved year annual growth rate earnings per share grew rate worldwide net earnings billion reflecting increase worldwide net earnings per share equaled per share increase net earnings per share excluding impact iprd merger costs iprd net favorable adjustment costs associated global manufacturing restructuring charge worldwide net earnings billion net earnings per share representing increase respectively worldwide net earnings billion reflecting increase worldwide net earnings per share equaled per share increase net earnings per share excluding impact iprd net favorable adjustment costs associated global manufacturing restructuring charge merger costs worldwide net earnings billion net earnings per share representing increase respectively cash flows liquidity cash generated operations selected borrowings provide major sources funds growth business including working capital capital expenditures acquisitions share repurchases dividends debt repayments cash current marketable securities billion end compared billion end cash generated operations amounted billion less cash generated operations billion decrease due primarily funding us pension plan approximately million net current tax benefit change timing salary increases bonuses paid employees december february change enacted results finalized order align compensation performance result change increase approximately million cash flows operating activities due payment bonus capital expenditures capital expenditures increased billion increased billion increase due primarily expansion manufacturing facilities support new existing products investments support research investments information systems across business segmentsshare repurchases dividends february company announced stock repurchase program billion time limit program program completed august million shares repurchased aggregate price billion addition stock repurchase program company annual program repurchase shares use employee stock employee incentive plans company increased cash dividend th consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows table caption c c c first quarter second quarter third quarter fourth quarter total table january board directors declared regular cash dividend per share paid march shareholders record february company expects continue practice paying regular cash dividends contractual obligations commitments company longterm contractual obligations primarily lease debt obligations satisfy obligations company intends use cash operations following table summarizes company 's contractual obligations aggregate maturities december see notes details table caption operating debt millions dollars leases obligations c c table financial position capital resources total assets returns total assets increased billion billion consolidated assets yearend medical devices diagnostics accounted pharmaceutical segment assets consumer segment assets general corporate assets yearend consolidated assets identifiable medical devices diagnostics pharmaceutical segments respectively consumer segment general corporate assets respectively net intangible assets increased represented total assets yearend net property plant equipment increased billion represented total assets yearend shareholders ' equity per share end compared yearend decrease decrease primarily due billion stock repurchase program completed financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value existing foreign currency assets liabilities hedge future foreign currency product costs gains losses contracts offset primarily effect foreign exchange rate changes underlying transactions appreciation us dollarfrom december market rates would increase unrealized value company 's forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value company 's forward contracts million either scenario gain loss forward contract would offset effect foreign exchange rate changes underlying transaction company enters currency swap contracts manage company 's exposure changes currency exchange rates hedging foreign currency denominated assets liabilities impact change interest rates company 's interest rate sensitive financial instruments would immaterial company enter financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions company significant exposure one counterparty management believes risk loss remote total unused credit available company approximates billion including billion credit commitments billion uncommitted lines various banks worldwide expire company 's shelf registration filed securities exchange commission enables company issue billion unsecured debt securities warrants purchase debt securities medium term note mtn program mtn 's issued december company billion remaining shelf registration company continues one companies triple credit rating total borrowings end billion billion respectively net cash cash current marketable securities net debt billion net cash cash current marketable securities net debt billion total debt represented total capital shareholders ' equity total debt total capital period ended december material cash commitments summary borrowings found note company believes operations comply material respects applicable environmental laws regulations company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state laws relief sought cost past future remediation feasible predict determine outcome proceedings opinion company proceedings would material adverse effect results operations cash flows financial position company matters critical accounting policies estimates management 's discussion analysis results operations financial condition based company 's consolidated financial statements prepared accordance accounting principles generally accepted us preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company 's significant accounting policies described note however company believes understanding certain key accounting policies estimates essential achieving insight company 's operating results financial condition key accounting policies estimates include revenue recognition accounting income taxes legal self insurance contingencies valuation long lived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock options revenue recognition company recognizes revenue product sales goods shipped delivered depending title risk passes customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers provided reductions determining sales period related sales recorded provisions largest medicaid rebate provision based estimates derived current program requirements historical experience company also recognizes service revenue received copromotion certain products yearend december revenues less total revenues included product salesincome taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting us tax reporting recorded deferred tax assets liabilities company records deferred tax assets liabilities based current tax regulations rates changes tax laws rates may affect deferred tax assets liabilities recorded future management believes changes estimates would material effect company 's results operations cash flows financial position company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover repatriation undistributed earnings december december cumulative amount undistributed international earnings approximately billion billion respectively legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability cases arise normal course business accruals based management 's judgment probability losses opinions legal counsel applicable actuarially determined estimates additionally company records insurance receivable amounts third party insurers based probability recovery appropriate reserves receivables recorded estimated amounts may collected third party insurers long lived intangible assets company assesses changes economic conditions strategic priorities makes assumptions regarding estimated future cash flows evaluating value company 's fixed assets goodwill noncurrent assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans require assumptions discount rate expected return plan assets expected salary increases health care cost trend rates see note detail rates effect change rates company 's results operations stock options company elected use accounting principle board opinion accounting stock issued employees apb require compensation costs related stock options recorded net income options granted various stock option plans exercise price equal market value underlying common stock grant date statement financial accounting standard sfas accounting stockbased compensation transition disclosure amendment fasb statement requires pro forma disclosure net income earnings per share determined fair value method accounting stock options applied measuring compensation cost see notes information regarding stock options new accounting standards june fasb issued sfas accounting asset retirement obligations company adopt standard effective fiscal years beginning june expected material impact company 's results operations cash flows financial position august fasb issued sfas accounting impairment disposal longlived assets effective first quarter company 's adoption sfas material effect company 's results operations cash flows financial position june fasb issued sfas accounting costs associated exit disposal activities effective exit disposal activities initiated december company adopt sfas first quarter expected material effect company 's results operations cash flows financial positionon november fasb issued fasb interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others interpretation fasb statements rescission fasb interpretation fin clarifies requirements fasb statement accounting contingencies relating guarantor 's accounting disclosure issuance certain types guarantees disclosure requirements fin effective financial statements interim annual periods end december adopted company disclosure required yearend provisions initial recognition measurement effective prospective basis guarantees issued modified december irrespective guarantor 's yearend fin requires upon issuance guarantee entity must recognize liability fair value obligation assumes guarantee company 's adoption fin expected material effect company 's results operations cash flows financial position january fasb issued fin consolidation variable interest entities interpretation arb addresses consolidation variable interest entities fin expands criteria consideration determining whether variable interest entity consolidated business entity requires existing unconsolidated variable interest entities include limited special purpose entities spes consolidated primary beneficiaries entities effectively disperse risks among parties involved interpretation applies immediately variable interest entities created january variable interest entities enterprise obtains interest date applies first fiscal year interim period beginning june variable interest entities enterprise holds variable interest acquired february adoption fin expected material effect company 's results operations cash flows financial position changing prices inflation johnson johnson aware products used setting decade policymakers consumers businesses expressed concern rising cost health care response concerns johnson johnson longstanding policy pricing products responsibly period united states weighted average compound annual growth rate johnson johnson price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi period inflation rates even though moderate many parts world continue effect worldwide economies consequently way companies operate face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases common stock market prices company 's common stock listed new york stock exchange symbol jnj composite market price ranges johnson johnson common stock table caption high low high low c c c c first quarter second quarter third quarter fourth quarter yearend close table subsequent events february johnson johnson announced signed definitive agreement scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases company acquire scios cash stock exchange terms agreement scios shareholders receive outstanding scios share value transaction anticipated closing date expected approximately billion net cashanticipated acquired based scios ' approximately million fully diluted shares outstanding boards directors johnson johnson scios given approval transaction subject clearance hartscottrodino antitrust improvements act transaction also subject approval shareholders scios customary closing conditions scios biopharmaceutical company developing novel treatments cardiovascular inflammatory disease company 's diseasebased technology platform integrates expertise protein biology computational medicinal chemistry identify novel targets rationally design small molecule compounds large markets unmet medical needs scios ' product natrecor first novel agent approved congestive heart failure chf decade natrecor recombinant form naturally occurring protein secreted heart part body 's response chf drug several significant advantages existing therapies chf single common cause hospitalization united states patients principal focus scios ' research development program small molecule inhibitors includes several potential new treatments pain inflammatory diseases including advanced p kinase inhibitor program transaction expected close second quarter company anticipates iprd charge approximately million incurred connection acquisition cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forward looking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company assumes obligation update forwardlooking statements result new information future events developments company 's report year ended december filed march contain exhibit discussion various factors could cause actual results differ expectations prior filing investors reference company 's report fiscal year ended december company notes factors permitted private securities litigation reform act consolidated balance sheets johnson johnson subsidiaries december december dollars millions except share per share data note table caption c c assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes deferred taxes income note assets note total assets liabilities shareholders ' equity current liabilities loans notes payable note accounts payable accrued liabilities accrued salaries wages commissions taxes income total current liabilities longterm debt note deferred tax liability note employee related obligations note liabilities shareholders ' equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares note receivable employee stock ownership plan note accumulated comprehensive income note retained earnings less common stock held treasury cost note total shareholders ' equity total liabilities shareholders ' equity table see notes consolidated financial statements consolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note table caption c c c sales customers cost products sold gross profit selling marketing andadministrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes table see notes consolidated financial statements consolidated statements equity johnson johnson subsidiaries dollars millions note table caption note rec employee compre stock owner hensive retained ship plan total income earnings esop c c c c balance jan net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax curncy translation adj unrealized gainslosses securities pension liab adj reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax curncy translation adj unrealized gainslosses securities gainslosses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock comprehensive income net tax curncy translation adj unrealized gainslosses securities pension liab adj gainslosses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec table see notes consolidated financial statements consolidated statements equity johnson johnson subsidiaries dollars millions note table caption accumul common compre stock treasury hensive issued stock income amount amount c c c balance jan net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax curncy translation adj unrealized gainslosses securities pension liab adj reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock business combinations comprehensive income net tax curncy translation adj unrealized gainslosses securities gainslosses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec net earnings cash dividends paid employee stock compensation stock option plans conver subordinated debentures repurchase common stock comprehensive income net tax curncy translation adj unrealized gainslosses securities pension liab adj gainslosses derivatives hedges reclassification adj total comprehensive income note receivable esop bal dec table see notes consolidated financial statements consolidated statements cash flows johnson johnson subsidiaries dollars millions note table caption c c c cash flows operating activities net earnings adjustments reconcile net earnings cash flows depreciation amortization property intangibles purchased inprocess research development deferred tax provision accounts receivable reserves changes assets liabilities net effects acquisition businesses increase accounts receivable increase decrease inventories increase accounts payable accrued liabilities increase decrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisition businesses net cash acquired note purchases investments sales investments net cash used invest activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents decrease increase cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisition businesses fair value assets acquired fair value liabilities assumed treasury stock issued fair value net cash paid acquisitions table see notes consolidated financial statements notes consolidated financial statements summary significant accounting principles principles consolidation financial statements include accounts johnson johnson subsidiaries intercompany accounts transactions eliminated new accounting pronouncementsin june financial accounting standards board fasb issued statement financial accounting standard sfas accounting asset retirement obligations company adopt standard effective fiscal years beginning june expected material impact company 's results operations cash flows financial position august fasb issued sfas accounting impairment disposal longlived assets effective first quarter company 's adoption sfas material effect company 's results operations cash flows financial position june fasb issued sfas accounting costs associated exit disposal activities effective exit disposal activities initiated december company 's adoption sfas first quarter expected material effect company 's results operations cash flows financial position november fasb issued fasb interpretation fin guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others interpretation fasb statements rescission fasb interpretation fin clarifies requirements fasb statement accounting contingencies relating guarantor 's accounting disclosure issuance certain types guarantees disclosure requirements fin effective financial statements interim annual periods end december disclosure provisions implemented disclosures required yearend provisions initial recognition measurement effective prospective basis guarantees issued modified december irrespective guarantor 's yearend fin requires upon issuance guarantee entity must recognize liability fair value obligation assumes guarantee company 's adoption fin expected material effect company 's results operations cash flows financial position january fasb issued fin consolidation variable interest entities interpretation arb addresses consolidation variable interest entities fin expands criteria consideration determining whether variable interest entity consolidated business entity requires existing unconsolidated variable interest entities include limited special purpose entities spes consolidated primary beneficiaries entities effectively disperse risks among parties involved interpretation applies immediately variable interest entities created january variable interest entities enterprise obtains interest date applies first fiscal year interim period beginning june variable interest entities enterprise holds variable interest acquired february adoption fin expected material effect company 's results operations cash flows financial position cash equivalents company considers securities maturities three months less purchased cash equivalents investments shortterm marketable securities carried cost approximates fair value longterm debt securities company ability intent hold maturity carried amortized cost also approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments nonmarketable equity securities impairment adjusts investments fair value decline market value deemed temporary property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs incurredin connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally ranges years company reviews longlived assets assess recoverability using undiscounted cash flows necessary charges impairments longlived assets recorded amount present value future cash flows less carrying value assets revenue recognition company recognizes revenue product sales goods shipped delivered depending title risk passes customer provisions certain rebates sales incentives trade promotions product returns discounts customers provided reductions determining sales period related sales recorded sales incentives trade promotional allowances company adopted emerging issues task force eitf issue accounting consideration given vendor customer reseller vendor 's products effective december prior periods restated reclassify sales incentives trade promotional allowances selling general administrative expenses either reduction sales cost sales sales reduced million million respectively cost products sold increased million million respectively shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling immaterial periods presented inventories inventories stated lower cost market determined firstin firstout method intangible assets accordance sfas amortization recorded goodwill andor intangible assets deemed indefinite lives acquisitions completed june effective beginning fiscal year accordance sfas company discontinued amortization relating existing goodwill indefinite lived intangible assets effect nonamortization goodwill intangible assets approximately million tax intangible assets finite useful lives continue amortized useful lives sfas requires goodwill non amortizable intangible assets assessed annually impairment required initial assessment completed june impairment determined initial impairment assessment updated fourth quarter impairment determined future impairment tests performed fourth quarter annually financial instruments effective january company adopted sfas accounting derivative instruments hedging activities amended sfas accounting certain derivative instruments certain hedging activities amendment fasb statement collectively referred sfas sfas requires derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction depending type hedge transaction company uses forward exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product third party purchases raw materials denominated foreign currency company also uses currency swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses forward exchange contracts offset exposure certain foreign currencyassets liabilities forward exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities designation cash flow hedge made date entering derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction fair value forward exchange contract represents present value change forward exchange rates times notional amount derivative fair value currency swap contract determined discounting present future cash flows currencies exchanged interest rates prevailing market periods currency exchanges due expressing result us dollars current spot foreign currency exchange rate ongoing basis company assesses whether derivative continues highly effective offsetting changes cash flows hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposure 's impact company 's financial performance protect company 's cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available receivables insurance recoveries related product liability related claims recorded undiscounted time value money basis probable recovery realized research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization advertising costs associated advertising expensed year incurred advertising expenses worldwide comprised television radio print media well internet advertising billion billion billion income taxes company intends continue reinvest undistributed international earnings expand international operations therefore us tax expense recorded cover repatriation undistributed earnings december december cumulative amount undistributed international earnings approximately billion billion respectively deferred income taxes recognized tax consequences temporary differences applying enacted statutory tax rates applicable future years differences financial reporting tax basis existing assets liabilities net earnings per sharebasic earnings per share computed dividing net income available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities contracts issue common stock exercised converted common stock stock options december company stockbased employee compensation plans described note company accounts plans recognition measurement principles accounting principle board opinion accounting stock issued employees related interpretations compensation costs recorded net income stock options options granted plans exercise price equal market value underlying common stock date grant required sfas accounting stockbased compensation transition disclosure amendment fasb statement following table shows estimated effect net income earnings per share company applied fair value recognition provision sfas accounting stockbased compensation stockbased employee compensation table caption dollars millions except per share data c c c net income reported less compensation expense pro forma earnings per share basic reported pro forma diluted reported pro forma table determined fair value based method awards net tax risks uncertainties preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported actual results may may differ estimates annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years case fiscal year consists weeks reclassification certain prior year amounts reclassified conform current year presentation stock split april board directors declared stock split shareholders record close business may issued one additional share johnson johnson common stock june share held record date shares per share data periods presented financial statements adjusted reflect stock split inventories end inventories comprised tablecaption dollars millions c c raw materials supplies goods process finished goods table property plant equipment end property plant equipment cost accumulated depreciation table caption dollars millions c c land land improvements buildings building equipment machinery equipment construction progress less accumulated depreciation table company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal fixed assets cost related amount accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds adjusted earnings rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases amounted approximately million million million approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december table caption dollars millions total c c c c c c c table commitments capital leases significant employee related obligations end employee related obligations table caption dollars millions c c pension benefits post retirement benefits post employment benefits deferred compensation current benefits payable employee related obligations table prepaid employee related obligations million included assets consolidated balance sheet borrowings components longterm debt follows table caption eff eff dollars millions rate rate c c c c zero coupon convertible subordinated debentures due zero coupon convertible subordinated debentures due debentures due notes due debentures due notes due eurodollar notes due notes due notes due industrial revenue bonds principally international less current portion table weighted average effective rate represents us dollar notes due issued japanese subsidiary converted fixed rate yen note via currency swap company access substantial sources funds numerous banks worldwide total unused credit available company approximates billion including billion credit commitments billion uncommitted lines various banks worldwide expire interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material company 's shelf registration filed securities exchange commission enables company issue billion unsecured debt securities warrants purchase debt securities medium term note mtn program mtn 's issued december company billion remaining shelf registration long term debt includes two convertible subordinated debentures issued alza prior merger johnson johnson july alza completed private offering zero coupon convertible subordinated debentures issued price per principal amount maturity december outstanding debentures total principal amount maturity billion yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debenturesholders entitled convert debentures approximately million shares johnson johnson stock price per share approximately shares issued december due voluntary conversions note holders option holder debentures may repurchased company july purchase price equal issue price plus accreted original issue discount purchase date company option may elect deliver either johnson johnson common stock cash combination stock cash event repurchase debentures company option may also redeem debentures july issue price plus accreted original issue discount december december fair value based quoted market value debentures million million respectively alza issued zero coupon convertible subordinated debentures price per principal amount maturity december outstanding debentures total principal amount maturity million yield maturity per annum computed semiannual bond equivalent basis periodic interest payments terms debentures note holders entitled convert debentures approximately million shares johnson johnson stock price per share approximately million shares johnson johnson stock issued december due voluntary conversions note holders option holder debentures may purchased company july july purchase price equal issue price plus accreted original issue discount purchase date december december fair value based quoted market value debentures million million respectively shortterm borrowings current portion longterm debt amounted billion end borrowings comprised billion commercial paper million local borrowings principally international subsidiaries aggregate maturities longterm obligations commencing table caption dollars millions c c c c c c table intangible assets end gross net amounts intangible assets table caption dollars millions c c goodwill gross less accumulated amortization goodwill net trademarks nonamortizable gross less accumulated amortization trademarks nonamortizable net patents trademarks gross less accumulated amortization patents trademarks net intangibles gross less accumulated amortization intangibles net total intangible assets gross less accumulated amortization total intangible assets net table goodwill december allocated segments business follows table caption med dev dollars millions consumer pharm diag total c c c c goodwill net accumulated amortization december reclassification intangibles net accumulated amortization acquisitions translation goodwill december table weighted average amortization periods patents trademarks intangible assets years years respectively amortization expense amortizable intangible assets fiscal year ended december million pretax estimated amortization expense five succeeding years approximates million pretax per year respectively income taxes provision taxes income consists table caption dollars millions c c c currently payable us taxes international taxes deferred us taxes international taxes table comparison income tax expense federal statutory rate company 's effective tax rate follows table caption dollars millions c c c us international earnings taxes income statutory taxes tax rates statutory puerto rico ireland operations research tax credits domestic state local international subsidiaries excluding ireland iprd effective tax rate table company subsidiaries operating puerto rico tax incentive grant expiring addition company subsidiaries manufacturing ireland incentive tax rate effective year temporary differences carry forwards follows table caption deferred tax deferred tax dollars millions asset liab asset liab c c c c employee related obligations depreciation nondeductible intangibles international rd table table c c c c capitalized tax reserves liabilities income reported tax purposes miscellaneous international capitalized intangible miscellaneous us total deferred income taxes table difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating balance sheet assets liabilities current exchange rates except located highly inflationary economies reflected operating results analysis changes foreign currency translation adjustments included note net currency transaction translation gains losses included expense aftertax losses million million million respectively common stock stock option plans stock compensation agreements december company stockbased compensation plans stock option plan company may grant options employees issued shares company 's common stock plus number shares available previous year issued well shares issued plan expired terminated without exercised shares outstanding contracts company 's employee stock option plans nonemployee director 's plan mitek cordis biosense gynecare centocor innovasive devices alza inverness stock option plans stock options generally expire years date granted vest service periods range one six years options granted current market price date grant shares available stock option plan future grants based issued shares year million shares could granted year years addition available shares described shares available future grants plan million end summary status company 's stock option plans december december december changes years ending dates presented table caption weighted options average shares thousands outstanding exercise price c c balance january options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance december options granted options exercised options canceledforfeited balance december table includes options issued replace inverness options outstanding granted prior acquisition year ended december change timing granting stock compensation options employees december february change enacted results finalized order align compensation performance timing grants followed fiscal average fair value options granted fair value estimated using blackscholes option pricing model based weighted average assumptions table caption c c c riskfree rate volatility expected life yrs yrs yrs dividend yield table following table summarizes stock options outstanding exercisable december table caption shares thousands outstanding exercisable average average exercise average exercise exercise price range options lifea price options price c c c c c table average contractual life remaining years stock options exercisable december december options average exercise price options average exercise price respectively segments business geographic areas see information segments business geographic areas accumulated comprehensive income components comprehensive incomeloss consist following table caption total unrld gains accum gains pens losses cur losses liab deriv comp trans sec adj hedg incloss dollars millions c c c c c jan changes dec changes transitionadjustment net change due hedging transactions net amount reclassed net earnings net changes dec changes net change due hedging transactions net amount reclassed net earnings net changes dec table total comprehensive income includes reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income included reclassification adjustment gains million realized sale equity securities associated tax expense million total comprehensive income included reclassification adjustment gains million associated tax expense million tax effect unrealized gainslosses equity securities benefit million expense million expense million tax effect gainslosses derivatives hedges benefit million expense million see note additional information relating derivatives hedging currency translation adjustments currently adjusted income taxes relate permanent investments nonus subsidiaries retirement pension plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care domestic retired employees dependents international employees covered government sponsored programs cost company significant retirement plan benefits primarily based employee 's compensation last three five years retirement number years service company 's objective funding domestic plans accumulate funds sufficient provide accrued benefits international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided certain countries united states funding pension plans common practice funding provides economic benefit consequently company several pension plans funded company fund retiree health care benefits advance right modify plans future net periodic benefit costs company 's defined benefit retirement plans benefit plans include followingcomponents table caption retirement plans benefit plans dollars millions c c c c c c service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial gains curtailments settlements net periodic benefit cost table net periodic income cost attributable domestic retirement plans million million million following tables provide weightedaverage assumptions used develop net periodic benefit cost actuarial present value projected benefit obligations table caption retirement plans benefit plans c c c c c c domestic benefit plans weighted average discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans weighted average discount rate expected longterm rate return plan assets rate increase compensation levels table health care cost trends united states projected annual rates individuals grading year beyond effect change assumed cost trends accumulated postretirement benefit obligation end would million increase million decrease effect service interest cost components net periodic postretirement benefit cost would million increase million decrease plan assets consist primarily listed common stocks us nonus equities fixed income investments fair value johnson johnson common stock plan assets million december following tables set forth change benefit obligations change plan assets yearend company 's defined benefit retirement plans benefit plans table caption retirement plans benefit plans dollars millions c c c c change benefit obligation benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial loss divestitures acquisitions curtailments settlements total benefits paid effect exchange rates benefit obligation end year change plan assets plan assets fair value beginning year table table c c c c actual return plan assets company contributions plan participant contributions divestitures benefits paid plan assets effect exchange rates plan assets fair value end year table amounts recognized company 's balance sheet consist following table caption retirement plans benefit plans dollars millions c c c c plan assets less projected benefit obligation unrecognized actuarial losses gains unrecognized prior service cost unrecognized net transition asset total recognized consolidated balance sheet book reserves prepaid benefits intangible assets accumulated comprehensive income total recognized consolidated balance sheet table minimum pension liability adjustment required actuarial present value accumulated benefits abo exceeds fair value plan assets accrued pension liabilities minimum pension liability adjustments million million respectively relate primarily plans outside us plans accumulated benefit obligations excess plan assets consist following table caption retirement plans benefit plans dollars millions c c c c accumulated benefit obligation projected benefit obligation plan assets fair value table marketable securities table caption december un un real real est net ized ized fair cost gains losses value c c c c money market funds commercial paper time deposits government securities obligations asset backed securities bank notes corporate debt securities total current marketable securities government securities asset backed securities bank notes corporate debt securities investments held trust total noncurrent marketable securities table table caption december un un real real est net ized ized fair cost gains losses value c c c c money market funds commercial paper time deposits government securities obligations asset backed securities bank notes corporate debt securities total current marketable securities government securities asset backed securities bank notes corporate debt securities investments held trust total noncurrent marketable securities table current marketable securities include billion billion classified cash equivalents balance sheet december december respectively financial instruments effective january company adopted sfas requiring derivative instruments recorded balance sheet fair value december balance deferred net losses derivatives included accumulated comprehensive income million aftertax additional information see note amount company expects million reclassified earnings next months result transactions expected occur period amount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative transactions third parties cause amount accumulated comprehensive income affect net earnings maximum length time company hedging months year ended december net impact hedges ' ineffectiveness company 's financial statements insignificant year ended december company recorded net gain million tax income expense net category consolidated statement earnings representing impact discontinuance cash flow hedges probable originally forecasted transactions occur end originally specified time period refer note disclosures movements accumulated comprehensive income concentration credit risk company invests excess cash deposits major banks throughout world high quality money market instruments refer note additional information company policy making investments commercial institutions least equivalent credit rating investments generally mature within six months company notincurred related losses savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employee 's contributions consistent provisions plan heshe eligible us salaried plan onethird company match paid company stock employee stock ownership plan esop establish esop company loaned million esop trust purchase shares company stock open market exchange company received note balance recorded reduction shareholders ' equity total contributions plans million million million mergers acquisitions certain businesses acquired million cash liabilities assumed million assumed acquisitions accounted purchase method accordingly results operations included accompanying consolidated financial statements respective dates acquisition acquisitions included tibotecvirco nv privatelyheld biopharmaceutical company focused developing antiviral treatments micro typing systems inc manufacturer reagents supplier distributed instruments known idmicro typing systemtm obtech medical ag privatelyheld company markets adjustable gastric band treatment morbid obesity excess purchase price estimated fair value tangible assets acquired entities amounted million allocated identifiable intangibles goodwill addition approximately million identified value inprocess research development iprd associated tibotecvirco nv obtech medical ag acquisitions iprd charge related tibotecvirco nv million associated two early stage hiv compounds value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factors ranging discount rate iprd charge related obtech medical ag million associated development current swedish adjustable gastric band sagb use united states well development next generation technology platform value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factor discount rate pro forma information provided since impact acquisitions material effect company 's results operations cash flows financial position june johnson johnson alza corporation alza completed merger two companies transaction accounted poolingofinterests alza approximately million shares outstanding million fully diluted basis exchanged approximately million shares johnson johnson common stock diluted basis adjusted stock options convertible debt number johnson johnson shares issued total approximately million holders alza common stock received share johnson johnson common stock valued per share alza researchbased pharmaceutical company leading drug delivery technologies company applies delivery technologies develop pharmaceutical products enhanced therapeutic value johnson johnson affiliate portfolios many world 's leading pharmaceutical companies certain businesses acquired billion billion cash liabilities assumed million shares company 's common stock issued treasury valued billion acquisitions accounted purchase method accordingly results operationshave included accompanying consolidated financial statements respective dates acquisition acquisitions included inverness medical technology supplier lifescan 's electrochemical products blood glucose monitoring following spinoff nondiabetes businesses heartport company develops manufactures products less invasive open chest minimally invasive heart operations including stopped heart beating heart procedures teramed inc earlystage medical device company developing endovascular stentgraft systems minimally invasive treatment abdominal aortic aneurysms peripheral occlusive disease babycenter llc internet content commerce company devoted supporting community expectant new mothers viactiv product line chewable calcium supplement mead johnson nutritionals division bristolmyers squibb inverness medical technology acquired enhance control primary supplier lifescan blood glucose monitoring products allow achievement operational synergies acquisition also provides key technology development future products approximately million identified value iprd associated inverness medical technology teramed inc acquisitions iprd charge primarily related inverness projects minimally invasive testing continuous monitoring insulin delivery value iprd calculated assistance third party appraiser using cash flow projections discounted risk inherent projects using probability success factors ranging discount rate used certain businesses acquired million acquisitions accounted purchase method accordingly results operations included accompanying consolidated financial statements respective dates acquisitions acquisitions included crescendo company formed alza purpose selecting developing commercializing human pharmaceutical products innovasive devices company manufactures sells devices sports medicine surgery soft tissue injuries atrionix inc development stage company whose primary product pulmonary ablation catheter treatment atrial fibrillation medtrex company develops manufactures electrosurgical generators disposable products st joseph aspirin business iprd writeoff associated atrionix inc alza 's crescendo acquisition million iprd charge primarily related atrionix project design catheter system used procedure blocks electrical impulses originating pulmonary veins cause atrial fibrillation value iprd calculated assistance third party appraiser using cash flow projection discounted risk inherent project discount rate used divestitures material effect company 's results operations cash flows financial position legal proceedings company involved numerous product liability cases united states many concern adverse reactions drugs medical devices damages claimed substantial company confident adequacy warnings instructions use accompany products feasible predict ultimate outcome litigation however company believes liability results cases substantially covered reserves established selfinsurance program commercially available excess liability insurance one group cases company concerns janssen pharmaceutica product propulsid withdrawn general sale restricted limited use wake publicity events numerous lawsuits filed janssen wholly owned subsidiary company company regarding propulsid state federal courts across country approximately cases currently pending including claims approximately plaintiffs recently filed mississippi avoid application tort reform legislation effective january cases likely filed mississippi yet served active cases individuals alleged died use propulsid actions seek substantial compensatory punitivedamages accuse janssen company inadequately testing warning drug 's side effects promoting label use overpromotion addition janssen company entered agreements various plaintiffs ' counsel halting running statutes limitations respect potential claims significant number individuals attorneys evaluate whether sue janssen company behalf september first plaintiffs rankin case comprises claims propulsid plaintiffs went trial state court claiborne county mississippi jury returned compensatory damage verdicts plaintiff amount million total million trial judge thereafter dismissed claims punitive damages march trial judge reduced verdicts total million denied motions janssen company new trial janssen company believe verdicts even reduced insupportable appealed view janssen company proof trial demonstrated none plaintiffs injured propulsid basis liability existed april state court judge new jersey denied plaintiffs ' motion certify national class propulsid users purposes medical monitoring refund costs purchasing propulsid effort appeal ruling denied june federal judge presiding propulsid multidistrict litigation new orleans louisiana similarly denied plaintiffs ' motion certify national class propulsid users plaintiffs multi district litigation said preserving right appeal ruling complaints filed janssen company include class action allegations could basis future attempts classes certified respect various propulsid actions janssen company dispute claims lawsuits vigorously defending except judgment settlement appropriate janssen company believe adequate selfinsurance reserves commercially available excess insurance respect cases communications company excess insurance carriers raised certain defenses liability policies however opinion company defenses pro forma lack substance carriers honor obligations policies company 's ortho biotech subsidiary party arbitration proceeding filed amgen ortho biotech 's licensor us nondialysis rights procrit amgen sought terminate ortho biotech 's us license rights collect substantial damages based alleged deliberate procrit sales ortho biotech early amgen 's reserved dialysis market october arbitrator issued decision rejecting amgen 's request terminate license finding material breach license however arbitrator found conduct ortho biotech early subsequently halted ortho biotech amounted nonmaterial breach license awarded amgen million damages company expensed third quarter amgen sought billion damages january arbitrator ruled amgen prevailing party arbitration entitling award reasonable attorneys ' fees costs amgen yet submitted application fees costs company expensed million fourth quarter connection outstanding claim patent infringement actions tried delaware federal court late cordis corporation subsidiary johnson johnson obtained verdicts infringement patent validity damage awards boston scientific corporation medtronic ave inc based number cordis coronary stent patents december jury damage action boston scientific returned verdict million december jury medtronic ave action returned verdict million sums represent lost profit reasonable royalty damages compensate cordis infringement include pre post judgment interest february hearing held claims boston scientific medtronic ave patents issue unenforceable owing alleged inequitable conduct patent office march may district judge issued post trial rulings confirmed validity enforceability main cordis stent patent claims found certain cordis patents unenforceable district judge granted boston scientific new trial liability damages vacated verdict medtronic ave legal grounds appeals federal circuit court appeals underway products various johnson johnson operating companies subject various patent lawsuits could potentially affect ability operating companies sell products require payment past damages future royalties respect patent challenges generic pharmaceutical firms result introduction generic versions products question ensuing loss market share following patent lawsuits concern important products johnson johnson operating companies medtronic ave v cordis corporation action filed april federal court texas asserts certain patents owned medtronicave cordis bx velocitytm stent also stent structure used cyphertm drug eluting product trial date set action ortho pharmaceutical v barr laboratories inc pending federal court new jersey action filed june involves barr 's effort invalidate ortho 's patents covering ortho tricyclen oral contraceptive product trial yet scheduled case orthomcneil daiichi inc v mylan laboratories orthomcneil daiichi inc v teva pharmaceutical matters first filed february federal court west virginia second june federal court new jersey concern efforts mylan teva invalidate establish noninfringement patent covering levaquin levofloxacin tablets patent owned daiichi exclusively licensed orthomcneil mylan case trial set late trial date set teva matter janssen alza v mylan laboratories action filed federal district court vermont february concerns mylan 's effort invalidate assert noninfringement alza 's patent covering duragesic product trial likely spring respect matters johnson johnson operating company involved vigorously defending validity asserting infringement licensors ' patents product accused infringing patents held others defending claims company also involved number patent trademark lawsuits incidental business ultimate legal financial liability company respect claims lawsuits proceedings referred estimated certainty however opinion management based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities already accrued company 's consolidated balance sheet expected material adverse effect company 's consolidated financial position although resolution reporting period one matters could significant impact company 's results operations period earnings per share following reconciliation basic net earnings per share diluted net earnings per share years ended december december december table caption shares millions c c c basic earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares adjusted average shares outstanding diluted diluted earnings per share table diluted earnings per share calculation includes dilution effect convertible debt decrease interest expense million million million tax years respectively diluted earnings per share excludes million shares options years million shares options year exercise price options greater average market valueresulting antidilutive effect diluted earnings per share capital treasury stock changes treasury stock table caption dollars millions except treasury stock number shares thousands shares amount c c balance january employee compensation stock option plans conversion subordinated debentures repurchase common stock business combinations balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock business combinations balance december employee compensation stock option plans conversion subordinated debentures repurchase common stock balance december table shares common stock authorized issued shares end selected quarterly financial data unaudited selected unaudited quarterly data years summarized table caption dollars millions first second third fourth except per share amounts quarter quarter qtr qtr c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share tabletable caption dollars millions first second third fourth except per share amounts quarter quarter qtr qtr c c c c segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision table table c c c c taxes income net earnings basic net earnings per share diluted net earnings per share table second quarter includes tax charge million relating inprocess research development iprd costs third quarter includes tax charge million relating amgen arbitration settlement fourth quarter includes tax charge million relating amgen legal fees second quarter includes tax charge million relating alza merger costs third quarter includes tax charge million relating alza merger costs fourth quarter includes tax charge million relating iprd costs fourth quarter also includes tax charge million relating lifescan class action settlement subsequent event february johnson johnson announced signed definitive agreement scios inc biopharmaceutical company marketed product cardiovascular disease research projects focused autoimmune diseases company acquire scios cash stock exchange terms agreement scios shareholders receive outstanding scios share value transaction anticipated closing date expected approximately billion net cash anticipated acquired based scios ' approximately million fully diluted shares outstanding boards directors johnson johnson scios given approval transaction subject clearance hartscottrodino antitrust improvements act transaction also subject approval shareholders scios customary closing conditions scios biopharmaceutical company developing novel treatments cardiovascular inflammatory disease company 's diseasebased technology platform integrates expertise protein biology computational medicinal chemistry identify novel targets rationally design small molecule compounds large markets unmet medical needs scios ' product natrecor recombinant form naturally occurring protein secreted heart part body 's response congestive heart failure chf drug several significant advantages existing therapies chf single common cause hospitalization united states patients principal focus scios ' research development program small molecule inhibitors includes several potential new treatments pain inflammatory diseases including advanced p kinase inhibitor program transaction expected close second quarter independent auditor 's report shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings consolidated statements equity consolidated statements cash flows present fairly material respects financial position johnson johnson subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion discussed notes financial statements company adopted statement financial accounting standards goodwill intangible assets effective december pricewaterhousecooper llp new york new york january except note date february segments business johnson johnson subsidiaries table caption sales customers dollars millions c c c consumer domestic international total pharmaceutical domestic international total med devices diagnostics domestic international total worldwide total table table caption operating profit dollars millions c c c consumer pharmaceutical med devices diagnostics table table c c c segments total expenses allocated segments general corporate worldwide total table table caption identifiable assets dollars millions c c c consumer pharmaceutical med devices diagnostics segments total expenses allocated segments general corporate worldwide total table table caption additions property plant equipment dollars millions c c c consumer pharmaceutical med devices diagnostics segments total general corporate worldwide total table table caption depreciation amortization dollars millions c c c consumer pharmaceutical med devices diagnostics segments total general corporate worldwide total table geographic areas table caption sales customers dollars millions c c c united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total table table caption longlived assets dollars millions c c c united states europe western hemisphere excluding us table table c c c asiapacific africa segments total general corporate non longlived assets worldwide total table see management 's discussion analysis pages description segments company business export sales intersegment sales significant sales three distributors accounted total revenues sales concentrated pharmaceutical segment sales procriteprex accounted total company revenues respectively amounts allocated segments include interest incomeexpense minority interest general corporate income expense general corporate includes cash marketable securities includes million inprocess research development iprd million million amgen costs pharmaceutical segment million iprd medical devices diagnostics segment includes million alza merger costs pharmaceutical segment million iprd million class action settlement medical devices diagnostics segment includes restructuring gains million consumer segment million million iprd charges net restructuring gains pharmaceutical medical devices diagnostics segments respectively summary operations statistical data johnson johnson subsidiaries dollars millions except per share figures table caption c c c c c c c c sales customers domestic sales customers international total sales cost products sold selling marketing admin expenses research expense purchased inprocess research develop interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income earnings cumulative effect accounting changes cumulative effect accounting changes net tax net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders ' equity table percent increase decrease previous year table c c c c c c c c sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maint repairs total tax expense table supplementary balance sheet data table c c c c c c c c property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table dollars millions except per share figures table caption c c c sales customers domestic sales customers international total sales cost products sold selling marketing admin expenses research expense purchased inprocess research develop interest income interest expense net portion capitalized income expense net earnings provision taxes income provision taxes income earnings cumulative effect accounting changes cumulative effect accounting changes net tax net earnings percent sales customers diluted net earnings per share common stock percent return average shareholders ' equity table percent increase decrease previous year table c c c sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maint repairs total tax expense table supplementary balance sheet data table c c c property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders ' equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands table adjusted reflect twoforone stock split excluding cumulative effect accounting changes million earnings percent sales customers accounting changes earnings per share accounting change earnings percent return average shareholders ' equity accounting changes diluted net earnings per share percent increase prior year accounting changes diluted net earnings per share increase prior year excluding inprocess research development iprd merger restructuring costs diluted net earnings per share increase prior year diluted net earnings per share increase prior year diluted net earnings per share increase prior year diluted net earnings per share increase prior year diluted net earnings per share increase prior year cost products sold includes million inventory writeoffs restructuring percent return average shareholders ' equity earnings percent sales customers diluted net earnings per share increase prior year periods adjusted include effects alza merger net interest income also included cost materials services category includes taxes income payroll property business taxes text document document typeex sequence filenameyexvtxt descriptionsubsidiaries text exhibit subsidiaries johnson johnson new jersey corporation domestic international subsidiaries shown certain domestic subsidiaries international subsidiaries named significant aggregate johnson johnson parent table caption jurisdiction name subsidiary organization c domestic subsidiaries alza corporation delaware alza land management inc delaware biosense webster inc california centocor inc pennsylvania codman shurtleff inc new jersey cordis corporation floridacordis international corporation delaware cordis llc delaware crescendo pharmaceuticals corporation delaware depuy inc delaware depuy acromed inc ohio depuy acromed sales limited partnership massachusetts depuy orthopaedics inc indiana depuy products inc indiana diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware gynopharma inc delaware heartport inc delaware independence technology llc new jersey innovasive devices inc massachusetts iso merger corp delaware janssen finance company florida janssen inc delaware janssen ortho llc delaware janssen pharmaceutica inc pennsylvania janssen pharmaceutica products lp new jersey johnson johnson consumer companies inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceuticals co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson professional co pr inc delaware table table caption jurisdiction name subsidiary organization c johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical products corporation delaware jjhc inc delaware lifescan inc california lifescan llc delaware mcneilppc inc new jersey microsphere investments inc delaware ndc investment corporation delaware neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co florida orthomcneil pharmaceutical inc delaware roc usa corporation delaware rutan realty llc new jersey splenda inc delaware teramed corporation delaware tylenol company new jersey therakos inc florida winthorpe valentine inc delaware international subsidiaries abello farmacia sl italy alza ireland limited ireland apsis sarl france centra medicamenta otc srl italy cilag ag switzerland cilag ag international switzerlandcilag de mexico sa de cv mexico cilag holding ag switzerland cordis europa nv netherlands cordis italia spa italy cordis medizinische apparate gmbh germany cordis de mexico sa de cv mexico cordis sa france cordis sarl switzerland depuy ace sarl switzerland depuy australia pty ltd australia depuy france sa france table table caption jurisdiction name subsidiary organization c depuy international ltd united kingdom depuy intl holdings ltd united kingdom depuy ireland limited ireland depuy japan kk japan depuy orthopedie sa france depuy spa italy depuy uk holdings limited united kingdom ethicon endosurgery europe gmbh germany ethicon gmbh germany ethicon ireland limited ireland ethicon limited scotland ethicon sas france ethicon spa italy ethnor proprietary limited south africa greiter ag switzerland greiter international ag switzerland inverness medical limited scotland janssen animal health bvba belgium janssencilag norway janssencilag ab sweden janssencilag ag switzerland janssencilag denmark janssencilag bv netherlands janssencilag egypt ltd egypt janssencilag ca venezuela janssencilag farmaceutica ltda brazil janssencilag farmaceutica lda portugal janssencilag farmaceutica srl argentina janssencilag ltd united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag pty limited australia janssencilag sa spain janssencilag sa france janssencilag spa italy janssen farmaceutica sa de cv mexico janssencilag gmbh germany janssen internationaal cvba belgium janssen korea ltd korea janssenortho inc canada janssen pharmaceutica limited thailand janssen pharmaceutica nv belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical limited ireland table table caption jurisdiction name subsidiary organization c jc healthcare ltd israeljhc nederland bv netherlands johnson johnson ag switzerland johnson johnson sa de cv mexico johnson johnson de argentina sace argentina johnson johnson china investment co ltd china johnson johnson china ltd china johnson johnson comercio e distribuicao ltda brazil johnson johnson consumer france sas france johnson johnson consumer nvsa belgium johnson johnson de colombia sa colombia johnson johnson de venezuela sa venezuela johnson johnson del ecuador sa ecuador johnson johnson egypt sae egypt johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gmbh germany johnson johnson gesellschaft mbh austria johnson johnson group holdings gmbh germany johnson johnson hellas sa greece johnson johnson holding ab sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson international financial services company ireland johnson johnson international sa france johnson johnson investments limited united kingdom johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson kft hungary johnson johnson kk japan johnson johnson korea ltd korea johnson johnson lda portugal johnson johnson ltd united kingdom johnson johnson limited india johnson johnson msd consumer pharmaceuticals sas france johnson johnson management limited united kingdom johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nvsa belgium johnson johnson medical pty ltd south africa johnson johnson medical pty limited australia johnson johnson medical shanghai ltd china johnson johnson medical sa argentina table table caption jurisdiction name subsidiary organization c johnson johnson morocco sa morocco johnson johnson new zealand limited new zealand johnson johnson pacific pty ltd australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland sp z oo poland johnson johnson private limited zimbabwe johnson johnson products inc canada johnson johnson produtos profissionais ltda brazil johnson johnson professional products proprietary ltd south africa johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty limited australia johnson johnson sa de cv mexico johnson johnson sa spain johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson spolsro czech republic johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson de venezuela sa venezuelajohnson johnson zambia limited zambia laboratoires martin johnson johnson msd sas france laboratoires polive snc france lifescan canada ltd canada mcneil consumer nutritionals europe switzerland medos sa switzerland neutrogena limited england neutrogena provence sarl france obtech medical ag switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostics gmbh germany orthoclinical diagnostics kk japan orthoclinical diagnostics united kingdom orthoclinical diagnostics nv belgium orthoclinical diagnostics sa france orthoclinical diagnostics spa italy penta pty limited australia pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china shanghai johnson johnson limited china tasmanian alkaloids pty ltd australia rw johnson pharmaceutical research institute switzerland tibotec bvba belgium tibotec pharmaceuticals ltd ireland table table caption jurisdiction name subsidiary organization c tibotecvirco comm va belgium vania expansion snc france woelm pharma gmbh co germany xianjanssen pharmaceutical ltd china table text document document typeex sequence filenameyexvtxt descriptionconsent independent accountants text exhibit consent independent accountants hereby consent incorporation reference registration statements form file form file report dated january except note date february relating financial statements johnson johnson appears annual report shareholders incorporated annual report also consent incorporation reference report dated january relating financial statement schedule appears pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york march text document document typeexbsequence filenameyexvwbtxt descriptioncautionary statement text exhibit b cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts anticipate results based management 's plans subject uncertainty forwardlooking statements may identified use words like plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance company 's strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncertainties materialize actual results could vary materially company 's expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company assumes obligation update forwardlooking statements result new information future events developments important factors could cause company 's actual results differ company 's expectations forwardlooking statements follows economic factors including inflation fluctuations interest rates foreign currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors including fact new competition us procrit topselling product company 's portfolio challenges company 's patents competitors could potentially affect company 's ability sell products question require payment past damages future royalties generic pharmaceutical firms result introduction generic versions products ensuing loss market share financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase company 's products pay products previously purchased meet obligations company supply arrangements impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions interruptions computer communication systems including computer viruses could impair company 's ability conduct business communicate internally customers domestic foreign health care changes resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment government laws regulations relating sales promotion reimbursement pricing generally government laws regulations affecting domestic foreign operations including relating trade monetary fiscal policies taxes price controls regulatory approval new products licensing patent rights competition research involving development improvementof new existing products processes particularly significant results time time product process obsolescence development new improved products important company 's success areas business difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals united states abroad gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product significant litigation adverse company including product liability claims patent infringement claims antitrust claims product efficacy safety concerns resulting product recalls regulatory action part fda foreign counterparts declining sales impact business combinations including acquisitions divestitures internally company externally pharmaceutical health care industries issuance new revised accounting standards american institute certified public accountants financial accounting standards board securities exchange commission foregoing list sets forth many factors could impact upon company 's ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act text document secdocument end privacyenhanced message